nct_id,title,acronym,status,study_results,conditions,interventions,outcome_measures,sponsors,gender,min_age,max_age,age_groups,phases,enrollment,funded_bys,study_types,exp_acc_types,study_designs,other_ids,start_date,primary_completion_date,completion_date,study_first_posted,last_update_posted,locations,documents,url
NCT04372602,Duvelisib to Combat COVID-19, ,Recruiting,No Results Available,COVID-19,Duvelisib|Peripheral blood draw|Placebo,Overall survival|Length of hospital stay|Length of ICU stay|Duration of ventilator use|Duration of vasopressors use|Duration on renal replacement therapy|Viral kinetics as measured by virologic failure|Number of adverse events as measured by CTCAE v. 5.0,"Washington University School of Medicine|Verastem, Inc.",All,18 Years, ,Adult|Older Adult,Phase 2,28,Other|Industry,Interventional, ,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",202007009,"October 12, 2020","November 30, 2021","April 30, 2022","May 4, 2020","May 25, 2021","Missouri Baptist Medical Center, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States", ,https://ClinicalTrials.gov/show/NCT04372602
NCT04902157,Relationship Between CT- Value With Prognosis in COVID-19 Patients, ,Recruiting,No Results Available,COVID-19,Cycle threshold,prognosis,Shahid Beheshti University of Medical Sciences,All, , ,Child|Adult|Older Adult, ,60,Other,Observational, ,Observational Model: Cohort|Time Perspective: Prospective,SBMU.34.675,"February 1, 2021","January 1, 2022","February 1, 2022","May 26, 2021","May 26, 2021","SBMU, Tehran, Iran, Islamic Republic of|Nooshin Dalili, Tehran, Iran, Islamic Republic of", ,https://ClinicalTrials.gov/show/NCT04902157
NCT04364698,Observational Cohort of COVID-19 Patients at Raymond-Poincare,COVID-RPC,Recruiting,No Results Available,COVID-19, ,"clinical, biological and radiological characteristics|patients' journey description|Treatments effects",Assistance Publique - Hôpitaux de Paris,All,18 Years, ,Adult|Older Adult, ,500,Other,Observational, ,Observational Model: Cohort|Time Perspective: Prospective,20SBS-COVID-RPC,"May 7, 2020",June 2020,June 2020,"April 28, 2020","May 14, 2020","Department of Infectiology, Raymond Poincaré Hospital, APHP, Garches, France", ,https://ClinicalTrials.gov/show/NCT04364698
NCT04459637,COVID-19 Surveillance Based on Smart Wearable Device,COVID-19SWD,Not yet recruiting,No Results Available,COVID-19, ,"Deterioration of the condition|Mortality|The information analysis degree, the proportion of signal loss, the proportion of wrong signal,",Peking University First Hospital,All,18 Years,75 Years,Adult|Older Adult, ,200,Other,Observational, ,Observational Model: Cohort|Time Perspective: Prospective,2020055-0615,"July 1, 2020","March 10, 2021","March 10, 2021","July 7, 2020","July 7, 2020","Peking University First Hospital, Beijing, Beijing, China", ,https://ClinicalTrials.gov/show/NCT04459637
NCT04425538,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19)., ,Completed,Has Results,COVID-19,Infliximab,Time to Improvement in Oxygenation|Incidence of Improvement in Oxygenation|28-Day Survival Status|Duration of Supplemental Oxygen Administration by Nasal Cannula|Duration of Non-invasive Ventilation or by Non-rebreather Mask or High-flow Nasal Cannula|Incidence of Mechanical Ventilation|Incidence of Vasopressor Support|Incidence of Extracorporeal Membrane Oxygenation|Incidence of Fever|Correlation of Cytokine Profile to Clinical Outcomes Specified in Primary and Secondary Objectives|Duration of Hospitalization|Incidence of Secondary Infections|Incidence of Supplemental Oxygen Administration by Nasal Cannula|Duration of Mechanical Ventilation|Incidence of Non-invasive Ventilation or by Non-rebreather Mask or High-flow Nasal Cannula|Assessment of Cytokine and Inflammatory Profile at Baseline and at 48 Hours After Therapy,Tufts Medical Center|National Institutes of Health (NIH),All,18 Years, ,Adult|Older Adult,Phase 2,17,Other|NIH,Interventional, ,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00000564,"June 1, 2020","January 22, 2021","January 22, 2021","June 11, 2020","December 3, 2021","December 3, 2021","Tufts Medical Center, Boston, Massachusetts, United States","
        |Study Protocol and Statistical Analysis Plan|https://ClinicalTrials.gov/ProvidedDocs/38/NCT04425538/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04425538
NCT05175846,INFLAMmatory BiomarkErs in COVID-19 Participants and Severity of Disease,INFLAME COVID,Not yet recruiting,No Results Available,COVID-19, ,To identify immunological and inflammatory biomarkers in participants with and without COVID-19 that may predict a participant's potential risk for severity of disease.|To correlate the biomarkers at baseline with the duration of symptoms up to six months in participants who develop COVID-19.,"Trinitas Global, LLC|AccessDx Laboratories, Houston, TX",All,18 Years, ,Adult|Older Adult, ,60,Industry|Other,Observational, ,Observational Model: Cohort|Time Perspective: Prospective,001,January 2022,"June 30, 2022","January 31, 2023","January 4, 2022","January 19, 2022","St Francis Hospital, Wilmington, Delaware, United States", ,https://ClinicalTrials.gov/show/NCT05175846
NCT05003271,Pulmonary Rehabilitation Post-COVID-19, ,Not yet recruiting,No Results Available,COVID-19,Exercise program (virtual/remote),Change in lung capacity|Change in dyspnea|Change in fatigue|Change in exercise capacity|Change in post-exercise saturation|Change in physical function|Change in activities participation|Changes in health-related quality of life (HRQoL) assessed with the EQ-5D-5L|Changes in health-related quality of life (HRQoL) assessed with the Short form (SF)-36 questionnaire,"University of Manitoba|Health Sciences Centre Foundation, Manitoba|Health Sciences Centre, Winnipeg, Manitoba",All,18 Years, ,Adult|Older Adult,Not Applicable,24,Other,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,HS25183(B2021:101),October 2021,May 2022,July 2022,"August 12, 2021","October 7, 2021", , ,https://ClinicalTrials.gov/show/NCT05003271
NCT04547257,Safety & Effectiveness Evaluation of Seraph 100 in Treatment of Pts With COVID-19,CP022,Recruiting,No Results Available,COVID-19,Seraph 100,Change in Organ failure|Change in Organ Failure|All-cause mortality|Organ dysfunction-free days|Intensive Care Unit (ICU) complications|Ventilator-free days (VFDs)|Length of stay (LOS) at ICU and hospital ward|Prognosis Factors|Recurrence of sepsis|Persistence of sepsis,ExThera Medical Europe BV|ExThera Medical Corporation|Vivantes Klinikum Neukölln,All,18 Years,90 Years,Adult|Older Adult,Not Applicable,42,Industry|Other,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CP022,"May 4, 2021","July 31, 2022","December 31, 2022","September 14, 2020","January 6, 2022","Klinikum Aschaffenburg-Alzenau, Aschaffenburg, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|Universitätsklinikum Essen, Essen, Germany|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Clinico San Carlos, Madrid, Spain", ,https://ClinicalTrials.gov/show/NCT04547257
NCT04454307,Safety and Efficacy of Tramadol in COVID-19 Egyptian Patients, ,Not yet recruiting,No Results Available,COVID-19,Tramadol|Standard care delivered in the isolation hospitals.,Number of COVID-19 PCR negative cases,Tanta University,All,18 Years,65 Years,Adult|Older Adult,Phase 1|Phase 2,100,Other,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",TRAM/COVID19,July 2020,August 2020,October 2020,"July 1, 2020","July 2, 2020", , ,https://ClinicalTrials.gov/show/NCT04454307
NCT04452435,Safety and Efficacy of C21 in Subjects With COVID-19, ,Completed,Has Results,COVID-19,C21|Placebo,Change From Baseline in C-reactive Protein (CRP) After Treatment With C21 200 mg Daily Dose (100 mg b.i.d.)|Change From Baseline in Body Temperature|Change From Baseline in IL-6|Change From Baseline in IL-10|Change From Baseline in TNF|Change From Baseline in CA125|Change From Baseline in Ferritin|Number of Subjects Not in Need of Oxygen Supply|Number of Subjects Not in Need of Mechanical Invasive or Non-invasive Ventilation|Time to Need of Mechanical Invasive or Non-invasive Ventilation|Time on Oxygen Supply (for Those Not Needing Mechanical Invasive or Non-invasive Ventilation)|Adverse Events,Vicore Pharma AB|Orphan Reach,All,18 Years,70 Years,Adult|Older Adult,Phase 2,206,Industry|Other,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",VP-C21-006|2020-001502-38,"July 21, 2020","October 13, 2020","October 13, 2020","June 30, 2020","April 30, 2021","June 23, 2021","Department of Medicine, Civil Hospital and B J Medical College, Ahmadabad, Gujarat, India|Infectious Disease, Metas Adventist Hospital, Surat, Gujarat, India|Clinical Research Department, Basement, Unity Trauma Centre and ICU (Unity Hospital, Surat, Gujarat, India|First Floor Clinical Research Department Rhythm Heart Institute, Vadodara, Gujarat, India|Internal Medicine S.L. Raheja Hospital, Mumbai, Maharashtra, India|Department of Medicine, Government Medical College and Hospital, Nagpur, Maharashtra, India|Neuro Critical Care, Grant Medical Foundation Ruby Hall Clinic, Pune, Maharashtra, India|Department of Medicine, Noble Hospitals Pvt. Ltd, Pune, Maharashtra, India|Respiratory Medicine, University College Hospital, London, United Kingdom","
        |Study Protocol and Statistical Analysis Plan: Study Protocol|https://ClinicalTrials.gov/ProvidedDocs/35/NCT04452435/Prot_SAP_000.pdf|
        |Statistical Analysis Plan: Statistical Analysis Plan|https://ClinicalTrials.gov/ProvidedDocs/35/NCT04452435/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04452435
NCT04333550,Application of Desferal to Treat COVID-19, ,Recruiting,No Results Available,COVID-19,Deferoxamine,Mortality rate|change in patients clinical manifestation|change in patients PaO2|Length of hospitalization|C-reactive protein|lymphocyte count|length of intensive care unit stay,Kermanshah University of Medical Sciences,All,3 Years,99 Years,Child|Adult|Older Adult,Phase 1|Phase 2,50,Other,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1398.1224,April 2020,September 2020,March 2021,"April 3, 2020","May 4, 2020","Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of", ,https://ClinicalTrials.gov/show/NCT04333550
NCT04432987,Dornase Alpha for the Treatment of COVID-19, ,Recruiting,No Results Available,COVID-19,Pulmozyme,Response|Survival,Acibadem University|The Scientific and Technological Research Council of Turkey,All,18 Years, ,Adult|Older Adult,Phase 2,60,Other,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,8820,"May 25, 2020","August 25, 2020","September 25, 2020","June 16, 2020","June 16, 2020","Acıbadem Altunizade Hospital, Istanbul, Turkey", ,https://ClinicalTrials.gov/show/NCT04432987
NCT04537559,Impact of COVID-19 Outbreak on Non-COVID-19 Patients,NoCOVImpact,Enrolling by invitation,No Results Available,COVID-19, ,"Intra-hospital mortality|composite outcome (worsening during hospitalization)|Pathologies leading to hospitalization|overall mortality at 3 months (90 days)|Potentially avoidable readmission rate|mortality rate by pathology at 3 months|length of stay|rate of transfer to intermediate or intensive care|rate of transfer to rehabilitation care|specific gravity outcomes for patients with pneumonia : CURB 65 scale (Confusion, Urea, Respiratory rate, Blood pressure, Age [>65])|specific gravity outcomes for patients with cardiac Failure : KILLIP class|specific gravity outcomes for patients with cardiac Failure : Weight variation|specific gravity outcomes for patients with cardiac Failure or lung disease|Leukocytes serum level|Polynuclear neutrophils serum level|Lymphocytes serum level|Hemoglobin serum level|Thrombocytes serum level|Quick serum level|INR (International Normalized Ratio)|fibrinogen serum level|PTT serum level (partial Thromboplastin time)|D-Dimers serum level|glucose serum level|glycated hemoglobin serum level (HbA1C)|C-reactive protein serum level (CRP)|sodium serum level|potassium serum level|chlorides serum level|calculated osmolality serum level|Phosphates serum level|corrected calcium serum level|urea serum level|creatinine serum level|eGFR (CKD-EPI) serum level|albumin serum level|prealbumin serum level|cyanocobalamin serum level|folate serum level|25-hydroxy vitamin D (D2 + D3) serum level|proBNP (Brain Natriuretic Peptid) serum level|Ultra sensitive Troponin T serum level|ASAT (aspartate transaminase) serum level|ALAT (alanine aminotransferase) serum level|Alkaline phosphatases serum level|Gamma glutamyl transpeptidase. serum level|Total bilirubin serum level|ferritin serum level|TSH serum level|Arterial pH|Arterial pCO2 (carbon dioxide partial pressure)|Arterial pO2 (oxygen partial pressure)|Arterial lactate|Arterial HCO3 (bicarbonate)|protein serum level|Arterial pressure|cardiac rates|respiratory rates|temperature|oxygen saturation|peak flow|specific scales : VAS of pain|specific scales : FIM|specific scales : SOFA score|specific scales : MNA|specific scales : NRS|serum or urine positive bacteriologic sample|Patient questionnaire","University Hospital, Geneva|Thomas Agoritsas|Sebastian Carballo|Pauline Darbellay|Olivier Grosgurin|Christophe Marti|Mathieu Nendaz|Jean-Luc Reny|Jacques Serratrice|Aimad Ourahmoune|Delphine Courvoisier|Virginie Prendki|Christine Serratrice|Dina Zekry|Omar Kherad|Eric Gerstel",All,16 Years, ,Child|Adult|Older Adult, ,40000,Other,Observational, ,Observational Model: Cohort|Time Perspective: Retrospective,2020-01017,"March 1, 2020","July 31, 2020","October 31, 2020","September 3, 2020","September 7, 2020","Geneva University Hospital, Geneva, Canton De Genève, Switzerland", ,https://ClinicalTrials.gov/show/NCT04537559
NCT04628143,A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia, ,Completed,No Results Available,COVID-19,Nafamostat Mesilate,Time to clinical improvement|Time to recovery|Proportion of patients with clinical improvement as defined by live discharge from hospital or a decline of 2 categories on the seven-category ordinal scale of clinical status,Chong Kun Dang Pharmaceutical,All,18 Years, ,Adult|Older Adult,Phase 2,13,Industry,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,A108_01CVD2013,"December 21, 2020","April 5, 2021","April 5, 2021","November 13, 2020","August 13, 2021","Korea Cancer Center Hospital, Seoul, Korea, Republic of", ,https://ClinicalTrials.gov/show/NCT04628143
NCT04869228,"A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients", ,Recruiting,No Results Available,COVID-19,GT0918 tablets or placebo,"Percentage of subjects requiring oxygen by Day 28|Percentage of subjects who experience the events(such as hospitalization,Death etc.) by Day 28. (not applicable for subjects whose countries require mild to moderate COVID-19 patients to be hospitalised, such as COVID-19 patients in mainland China)","Suzhou Kintor Pharmaceutical Inc,",Male,18 Years, ,Adult|Older Adult,Phase 3,724,Industry,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",GT0918-MR-3001,"August 4, 2021","February 28, 2022","May 30, 2022","May 3, 2021","October 19, 2021","Hospital Santa Paula, São Paulo, SP, Brazil", ,https://ClinicalTrials.gov/show/NCT04869228
NCT04568031,Study of AZD1222 for the Prevention of COVID-19 in Japan, ,Completed,No Results Available,COVID-19,AZD1222|0.9% (w/v) saline,"Proportion of participants who have a post treatment seroresponse to the spike antigens of AZD1222|The incidence of local and systemic solicited reactogenicity signs and symptoms for 7 days following throughout vaccination|The incidence of AEs, serious adverse events (SAEs) and adverse events of special interest (AESIs)|Biochemistry; change from baseline for blood chemistry measures|Haematology; change from baseline for hematology/hemostasis measures|Proportion of participants who have a post treatment|Genometric mean titres and genometric mean fold rise|Proportion of participants who have a post treatment seroresponse to AZD1222 as measured by SARS-CoV-2 nAbs|The incidence of serious adverse events (SAEs) and adverse events of specisl interest (AESIs) collected from Day1 through Day365",AstraZeneca|Iqvia Pty Ltd,All,18 Years, ,Adult|Older Adult,Phase 1|Phase 2,256,Industry,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",D8111C00002,"August 23, 2020","November 22, 2021","November 22, 2021","September 29, 2020","November 30, 2021","Research Site, Fukuoka-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Minato-ku, Japan|Research Site, Sumida-ku, Japan|Research Site, Toshima-ku, Japan", ,https://ClinicalTrials.gov/show/NCT04568031
NCT04336904,Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19, ,"Active, not recruiting",No Results Available,COVID-19,Favipiravir|Placebo,Time from randomization to clinical recovery|Time from randomization to negativity in RT-PCR nucleic acid test|Incidence of deterioration/aggravation of pneumonia|Time from randomization to resolution of pyrexia|Time from randomization to relief of cough|Time from randomization to relief of dyspnoea|Rate of auxiliary oxygen therapy|ICU admission rate|Mortality,Giuliano Rizzardini|ASST Fatebenefratelli Sacco,All,18 Years,75 Years,Adult|Older Adult,Phase 3,100,Other,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",HS216C17-PHASE III,"March 25, 2020",July 2020,July 2020,"April 7, 2020","April 8, 2020","Asst Fatebenefratelli Sacco, Milano, Italy", ,https://ClinicalTrials.gov/show/NCT04336904
NCT05074394,Randomized Study to Evaluate Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With Mild COVID-19 Infection,US,Withdrawn,No Results Available,COVID-19,COVI-DROPS|Placebo,Proportion of subjects who have a COVID-19-related visit or hospitalization|Viral load change from baseline to Day 15 (D15)|Proportion of subjects who have a COVID-19-related visit or hospitalization based on stratification groups,"Sorrento Therapeutics, Inc.",All,18 Years, ,Adult|Older Adult,Phase 2,0,Industry,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DRP-COV-206US,November 2021,November 2022,January 2023,"October 12, 2021","February 3, 2022", , ,https://ClinicalTrials.gov/show/NCT05074394
NCT04354831,A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection, ,"Active, not recruiting",No Results Available,COVID-19,anti-SARS-CoV-2 convalescent plasma,Overall Mortality within 60 days|Length of ICU stay during current admission for COVID,Medical College of Wisconsin|Froedtert Hospital,All,18 Years, ,Adult|Older Adult,Phase 2,131,Other,Interventional, ,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,PRO00037712,"May 11, 2020","May 1, 2022","May 1, 2023","April 21, 2020","November 15, 2021","Froedtert Hospital, Milwaukee, Wisconsin, United States", ,https://ClinicalTrials.gov/show/NCT04354831
NCT04582266,PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US, ,"Active, not recruiting",No Results Available,COVID-19,Remdesivir,"PK Outcome: Area under the plasma concentration-time curve (AUC) of RDV|PK Outcome: Half-life (t1/2) of RDV|PK Outcome: Trough concentration (Ctrough) of GS-441524|Safety Outcome: Maternal renal adverse event (AE) of any grade|Safety Outcome: Maternal hepatic AE of any grade|Safety Outcome: Maternal hematologic AE of any grade|Safety Outcome: Maternal Grade 3 or higher AE|Safety Outcome: Serious AE|Safety Outcome: Maternal Grade 3 or higher AE assessed as related to RDV by the Clinical Management Committee (CMC)|Safety Outcome: Pregnancy loss|Safety Outcome: Congenital anomalies|Safety Outcome: Preterm birth, defined as < 37 weeks|Safety Outcome: Preterm birth, defined as < 34 weeks|Safety Outcome: Small for gestational age, defined as < 10th percentile|Safety Outcome: Newborn birth weight|Safety Outcome: Newborn length|Safety Outcome: Newborn head circumference|PK Outcome: AUC of RDV|PK Outcome: t1/2 of RDV|PK Outcome: Ctrough of GS-441524|Safety Outcome: Renal AE of any grade|Safety Outcome: Hepatic AE of any grade|Safety Outcome: Hematologic AE of any grade|Safety Outcome: Grade 3 or higher AE|Safety Outcome: Grade 3 or higher AE assessed as related to RDV by the CMC",National Institute of Allergy and Infectious Diseases (NIAID),Female, , ,Child|Adult|Older Adult, ,40,NIH,Observational, ,Observational Model: Cohort|Time Perspective: Prospective,IMPAACT 2032|DAIDS Study ID 38746,"February 12, 2021","April 1, 2022","April 1, 2022","October 9, 2020","February 2, 2022","USC/Los Angeles County Medical Center NICHD CRS (5048), Los Angeles, California, United States|David Geffen School of Medicine at UCLA (CRS 5112), Los Angeles, California, United States|University California, San Diego (CRS 4601), San Diego, California, United States|Childrens Hospital (U. Colorado, Denver) NICHD CRS (5052), Denver, Colorado, United States|University of Florida (5051), Jacksonville, Florida, United States|Univ of Miami Pediatric/Perinatal HIV/AIDS (4201), Miami, Florida, United States|Emory University School of Medicine (CRS 5030), Atlanta, Georgia, United States|Ann & Robert H Lurie Children's Hospital of Chicago (4001), Chicago, Illinois, United States|Rush University Cook County Hospital NICHD CRS (5083), Chicago, Illinois, United States|Johns Hopkins University NICHD CRS (5092), Baltimore, Maryland, United States|Boston Medical Center Ped. HIV Program NICHD CRS (5011), Boston, Massachusetts, United States|Bronx-Lebanon Hospital Center (CRS 5114), Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS (5013), Bronx, New York, United States|Stony Brook University Medical Center (CRS 5040), Stony Brook, New York, United States|St. Jude Childrens Research Hosp, Memphis (6501), Memphis, Tennessee, United States|Texas Children's Hospital (Site 5128), Houston, Texas, United States|IMPAACT/ Gamma Project/ UPR Pediatric HIV/AIDS Research CRS, San Juan, Puerto Rico|University of Puerto Rico Pediatric HIV/AIDS CRS (6601), San Juan, Puerto Rico", ,https://ClinicalTrials.gov/show/NCT04582266
NCT04723394,Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults,TACKLE,"Active, not recruiting",No Results Available,COVID-19,AZD7442|Placebo,"A composite of either severe COVID-19 or death from any cause through Day 29.|AEs, SAEs, and AESIs through end of study.|A composite of either death from any cause or hospitalization for COVID-19 complications or sequelae during the 168-day post-dose period (Day 1 to Day 169).|The incidence of participants with respiratory failure, defined as requirement for mechanical ventilation, ECMO, non-invasive ventilation, or high-flow nasal cannula oxygen delivery.|COVID-19 symptom severity assessments based on symptom severity scores over time during the 28-day period from and including the day of the dose of AZD7442 or placebo.|Progression through Day 29 of one or more COVID-19-associated symptoms to a worse status than recorded in the participant-reported symptom diary at study entry, prior to start of AZD7442 or placebo.|Detection (detectable versus undetectable) from baseline of SARS-CoV-2 RNA from nasal swabs through Day 29.|Level of SARS-CoV-2 RNA from nasal swabs through Day 29.|Change from baseline of SARS-CoV-2 RNA from nasal swabs through Day 29.|Time to return to usual (pre-COVID-19) health through Day 29.|Duration of fever through Day 29 defined as the last day in the participant-reported symptom diary on which a temperature greater than 100°F (37.8° C) was recorded or a potentially antipyretic drug, such as acetaminophen or ibuprofen, was taken.|Incidence of ADA to AZD7442 in serum over time.|Pharmacokinetics - Serum Concentration|Pharmacokinetics - Maximum Serum Concentration|Pharmacokinetics - Time to Maximum Serum Concentration|Pharmacokinetics - Area under the plasma concentration-time curve to the last measurable time point|Pharmacokinetics - Area under the plasma concentration-time curve extrapolated to infinity",AstraZeneca,All,18 Years, ,Adult|Older Adult,Phase 3,910,Industry,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",D8851C00001,"January 28, 2021","August 21, 2021","October 21, 2022","January 25, 2021","September 20, 2021","Research Site, Jasper, Alabama, United States|Research Site, Tucson, Arizona, United States|Research Site, Long Beach, California, United States|Research Site, Northridge, California, United States|Research Site, Cutler Bay, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Pompano Beach, Florida, United States|Research Site, Chicago, Illinois, United States|Research Site, Lake Charles, Louisiana, United States|Research Site, Saint Louis, Missouri, United States|Research Site, La Vista, Nebraska, United States|Research Site, New York, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Statesville, North Carolina, United States|Research Site, Fargo, North Dakota, United States|Research Site, Columbus, Ohio, United States|Research Site, West Columbia, South Carolina, United States|Research Site, Dallas, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Humble, Texas, United States|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Ciudad de Buenos Aires, Argentina|Research Site, Munro, Argentina|Research Site, Blumenau, Brazil|Research Site, Porto Alegre, Brazil|Research Site, Ribeirão Preto, Brazil|Research Site, Sorocaba, Brazil|Research Site, São Paulo, Brazil|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Vratsa, Bulgaria|Research Site, Bilina, Czechia|Research Site, Hradec Kralove, Czechia|Research Site, Kolin, Czechia|Research Site, Ostrava, Czechia|Research Site, Svitavy, Czechia|Research Site, Berlin - Friedrichshain, Germany|Research Site, Berlin, Germany|Research Site, Berlin, Germany|Research Site, Frankfurt/Main, Germany|Research Site, Frankfurt, Germany|Research Site, Hamburg, Germany|Research Site, Hannover, Germany|Research Site, Koblenz, Germany|Research Site, Köln, Germany|Research Site, Mainz, Germany|Research Site, München-Pasing, Germany|Research Site, München, Germany|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Gyöngyös, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Tatabánya, Hungary|Research Site, Bologna, Italy|Research Site, Guastalla, Italy|Research Site, Milano, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Piacenza, Italy|Research Site, Pisa, Italy|Research Site, Roma, Italy|Research Site, Chiba-shi, Japan|Research Site, Hachioji-shi, Japan|Research Site, Iruma-Gun, Japan|Research Site, Kyoto-shi, Japan|Research Site, Maebashi-shi, Japan|Research Site, Narita-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinagawa-ku, Japan|Research Site, Shinjuku-ku, Japan|Research Site, Chihuahua, Mexico|Research Site, Cuauhtemoc, Mexico|Research Site, Cuautitlan Izcalli, Mexico|Research Site, Ecatepec de Morelos, Mexico|Research Site, Guadalajara, Mexico|Research Site, Guadalajara, Mexico|Research Site, Mazatlán, Mexico|Research Site, Monterrey, Mexico|Research Site, Mérida, Mexico|Research Site, Tlalpan, Mexico|Research Site, Tlalpan, Mexico|Research Site, Lima, Peru|Research Site, Rzeszów, Poland|Research Site, Wołomin, Poland|Research Site, Moscow, Russian Federation|Research Site, Murmansk, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, Cabra, Spain|Research Site, Centelles (Barcelona), Spain|Research Site, Girona, Spain|Research Site, Madrid, Spain|Research Site, Málaga, Spain|Research Site, Dnipro, Ukraine|Research Site, Ivano-Frankivsk, Ukraine|Research Site, Kherson, Ukraine|Research Site, Blackpool, United Kingdom|Research Site, Bracknell, United Kingdom|Research Site, Bristol, United Kingdom|Research Site, Cambridge, United Kingdom|Research Site, Connor Downs, United Kingdom|Research Site, Highgate, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Preston, United Kingdom|Research Site, Rochdale, United Kingdom", ,https://ClinicalTrials.gov/show/NCT04723394
NCT04540393,AZD1222 Vaccine for the Prevention of COVID-19, ,Withdrawn,No Results Available,COVID-19,AZD1222,Incidence of SAEs following the first vaccination and throughout the study duration (Day 180) [Safety and Tolerability].|Incidence of Solicited AEs for 7 following each vaccination [Safety and Tolerability].|SARS-CoV-2 antigen-specific antibody levels|The rate of participants seroconverting from negative to positive SARS-CoV-2 S antigen|The rate of participants seroconverting from negative to positive SARS-CoV-2 N|Quantity of SARS-CoV-2 neutralizing antibodies|Count of peripheral blood mononuclear cells (PBMCs)|Quantity of seasonal coronavirus antigens|Quantity of antibodies to the ChAdOx1vector and the persistence of these antibodies over time,AstraZeneca|Iqvia Pty Ltd|Covance,All,18 Years,130 Years,Adult|Older Adult,Phase 3,0,Industry,Interventional, ,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,D8111C00001,"September 2, 2020","December 4, 2020","May 11, 2022","September 7, 2020","October 1, 2021","Research Site, Moscow, Russian Federation|Research Site, Saint Petersburg, Russian Federation|Research Site, Saint-Petersburg, Russian Federation|Research Site, St. Petersburg, Russian Federation", ,https://ClinicalTrials.gov/show/NCT04540393
NCT04351802,CORonavirus (COVID-19) Diagnostic Lung UltraSound Study,COR-DLUS,Completed,No Results Available,COVID-19,Lung ultrasound,Diagnosis of COVID-19 on lung ultrasound|Difference in diagnosis of COVID-19 on lung ultrasound vs. chest x-ray|Diagnosis of alternative condition to COVID-19 on lung ultrasound vs. chest x-ray|Ability of surveillance lung ultrasound to predict clinical trajectory / outcome in patients with COVID-19|Consistency of lung ultrasound interpretation in patients presenting with suspected COVID-19,University Hospital Plymouth NHS Trust,All,18 Years, ,Adult|Older Adult, ,45,Other,Observational, ,Observational Model: Cohort|Time Perspective: Prospective,282661,"May 11, 2020","February 15, 2021","February 15, 2021","April 17, 2020","October 15, 2021","Derriford Hospital, Plymouth, Devon, United Kingdom", ,https://ClinicalTrials.gov/show/NCT04351802
NCT04883138,Recombinant Hyperimmune Polyclonal Antibody (GIGA-2050) in COVID-19 Patients, ,Terminated,No Results Available,COVID-19,GIGA-2050,"Incidence of treatment-emergent adverse events (TEAEs)|Incidence of dose limiting toxicities (DLTs)|Change from baseline of vital signs, physical examination, and clinical laboratory assessments|Incidence of infusion-related reactions (IRR) and hypersensitivity reactions|Pharmacological evaluation of single doses of GIGA-2050","GigaGen, Inc.",All,18 Years, ,Adult|Older Adult,Phase 1,3,Industry,Interventional, ,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,GG-GIGA-2050-001,"May 24, 2021","January 11, 2022","January 11, 2022","May 12, 2021","January 26, 2022","Icahn School of Medicine at Mount Sinai, New York, New York, United States", ,https://ClinicalTrials.gov/show/NCT04883138
NCT04359095,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia, ,Completed,No Results Available,COVID-19,Emtricitabine/tenofovir|Colchicine Pill|Rosuvastatin|Standard treatment,"Mortality|Number of Participants with Treatment Related Severe Adverse Events as Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection|Time to death|Number of Participants that are transferred to the Intensive Care Unit (ICU)|Number of Participants that need Mechanical Ventilation Support with endotracheal intubation.|Number of participants Cured assessed by Nasopharyngeal swab, oropharyngeal swab, and blood aspiration for COVID19 (RT-PCR) without clinical symptoms and normal chest X ray|Number of Participants with Any Adverse Event Related to Treatment Assessed by the NCORP Guidance for Collection of Adverse Events Related to COVID-19 Infection",Universidad Nacional de Colombia|Pontificia Universidad Javeriana|Clínica Colsanitas-Clínica Universitaria Colombia|Hospital Universitario San Ignacio|Hospital Universitario Nacional de Colombia (HUN)|Fundación Cardioinfantil Instituto de Cardiología|Clínica Infantil Santa María del Lago,All,18 Years, ,Adult|Older Adult,Phase 2|Phase 3,650,Other,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,76968,"August 18, 2020","March 20, 2021","June 30, 2021","April 24, 2020","August 12, 2021","Clinica santa Maria del lago, Bogota, DC, Colombia|Clínica Reina Sofía, Bogotá, Colombia|Fundacion Cardio Infantil, Bogotá, Colombia|Hospital Universitario San Ignacio, Bogotá, Colombia|Clinica Universitaria Colombia, Bogotá, Colombia|Hospital Universitario Nacional de Colombia, Bogotá, Colombia", ,https://ClinicalTrials.gov/show/NCT04359095
NCT05109546,Geriatric COVID-19 Serology,SeroGerCov,Recruiting,No Results Available,COVID-19, ,Retrospective study of COVID serologies in a geriatric population after infection or vaccination,"University Hospital, Strasbourg, France",All,76 Years, ,Older Adult, ,200,Other,Observational, ,Observational Model: Case-Only|Time Perspective: Retrospective,8438,"October 15, 2021",March 2022,"March 31, 2022","November 5, 2021","November 17, 2021","Service SSR Gériatrique - Hôpitaux Universitaires de Strasbourg, Strasbourg, France", ,https://ClinicalTrials.gov/show/NCT05109546
NCT05126498,Influence of the COVID-19 Pandemic on Dutch Surgical Patterns of Care, ,Completed,No Results Available,COVID-19,no intervention,Number of performed surgical procedures|Length of hospital stay (days)|30-day hospital readmissions (percentage)|severe complications (Clavien-Dindo grade > 3A)|ICU admission (percentage)|length of ICU stay (days)|mortality rate (percentage),University Medical Center Groningen,All,18 Years, ,Adult|Older Adult, ,40296,Other,Observational, ,Observational Model: Other|Time Perspective: Prospective,COVIDsurgII01,"August 1, 2020","May 1, 2021","May 1, 2021","November 19, 2021","November 19, 2021","UMCG, Groningen, Netherlands", ,https://ClinicalTrials.gov/show/NCT05126498
NCT04345445,Study to Evaluate the Efficacy and Safety of Tocilizumab Versus Corticosteroids in Hospitalised COVID-19 Patients With High Risk of Progression, ,Not yet recruiting,No Results Available,COVID-19,Tocilizumab|Methylprednisolone,The proportion of patients requiring mechanical ventilation|Mean days of ventilation|The proportion of patients requiring ICU admission|Overall 28-day survival|Change in symptom severity assessed by the World Health Organization (WHO) Coronavirus Disease 2019 (COVID19) ordinal scale measured daily up to 7 days from baseline|Duration of hospital and ICU stay,University of Malaya,All,18 Years, ,Adult|Older Adult,Phase 3,310,Other,Interventional, ,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TVCS-COVID19,"April 15, 2020","October 31, 2020","October 31, 2020","April 14, 2020","April 14, 2020","University Malaya Medical Centre, Kuala Lumpur, Malaysia", ,https://ClinicalTrials.gov/show/NCT04345445
NCT04508712,Long-term Outcomes in Patients With COVID-19, ,Recruiting,No Results Available,COVID-19, ,Physical functions|Respiratory function|Cognitive function|Depression status|Sensory functions|Heart function,RenJi Hospital,All,18 Years, ,Adult|Older Adult, ,900,Other,Observational, ,Observational Model: Case-Only|Time Perspective: Prospective,COVID-19 Prognosis,"August 10, 2020","August 31, 2021","August 31, 2021","August 11, 2020","October 23, 2020","Renji Hospital, Shanghai Jiaotong University School of Medicine, Pudong, Shanghai, China", ,https://ClinicalTrials.gov/show/NCT04508712
NCT05195229,Quantifying Viral Load in Respiratory Particles That Are Generated by Children and Adults With COVID-19 Infection, ,Recruiting,No Results Available,COVID-19,COVID-19 Aerosol Collection,Viral Load in Aerosols generated from COVID-19,Massachusetts General Hospital,All, , ,Child|Adult|Older Adult,Not Applicable,30,Other,Interventional, ,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,2020P002886,"January 13, 2022","March 1, 2022","May 1, 2022","January 18, 2022","January 18, 2022","Massachusetts General Hospital, Boston, Massachusetts, United States", ,https://ClinicalTrials.gov/show/NCT05195229
NCT04460547,Worldwide Trends on COVID-19 Research After the Declaration of COVID-19 Pandemic, ,Not yet recruiting,No Results Available,COVID-19,Convalescent Plasma Transfusion|Hydroxychloroquine|DAS181|Ivermectin|Interferon Beta-1A,"Geographical distribution of the interventional studies after 11th of March 2020.|Geographical distribution of the Observational studies after 11th of March 2020.|Monthly Research study completion rate as per geographic distribution of the Research.|Statistical correlation of the interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the observational studies Research with developed, developing and under developed countries.|Statistical correlation of the Drug based interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the Diagnostic test based interventional studies Research with developed, developing and under developed countries.|Statistical correlation of the Device based interventional studies Research with developed, developing and under developed countries.",Qassim University,All,1 Year, ,Child|Adult|Older Adult, ,200,Other,Observational, ,Observational Model: Cohort|Time Perspective: Retrospective,COAHS,"July 25, 2020","August 15, 2020","September 20, 2020","July 7, 2020","July 7, 2020", , ,https://ClinicalTrials.gov/show/NCT04460547
NCT04361422,Isotretinoin in Treatment of COVID-19,Randomized,Not yet recruiting,No Results Available,COVID-19,Isotretinoin Only Product in Oral Dose Form,Clinical clearance,Tanta University,All,18 Years,40 Years,Adult,Phase 3,300,Other,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,9469305c,"December 1, 2020",August 2021,December 2021,"April 24, 2020","September 23, 2020", , ,https://ClinicalTrials.gov/show/NCT04361422
NCT04625972,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults",STORM CHASER,"Active, not recruiting",No Results Available,COVID-19,AZD7442|Placebo,"The incidence of the first case of SARS CoV-2 RT PCR positive symptomatic illness|AEs, SAEs, MAAEs, and AESIs post dose of IMP|The incidence of SARS-CoV-2 RT-PCR-positive severe or critical symptomatic illness occurring after dosing with IMP|The incidence of participants who have a post-treatment response (negative at baseline to positive at any time post-baseline) for SARSCoV- 2 nucleocapsid antibodies|The incidence of COVID-19-related death occurring after dosing with IMP|The incidence of all-cause mortality occurring after dosing with IMP|Serum AZD7442 concentrations, PK parameters if data permit.|Incidence of ADA to AZD7442 in serum",AstraZeneca|Iqvia Pty Ltd,All,18 Years,120 Years,Adult|Older Adult,Phase 3,1121,Industry,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",D8850C00003,"December 2, 2020","April 7, 2021","June 19, 2022","November 12, 2020","December 8, 2021","Research Site, Guntersville, Alabama, United States|Research Site, Tempe, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Bakersfield, California, United States|Research Site, Corona, California, United States|Research Site, Garden Grove, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Huntington Park, California, United States|Research Site, Modesto, California, United States|Research Site, Coral Springs, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami Lakes, Florida, United States|Research Site, Miami Springs, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Mount Dora, Florida, United States|Research Site, North Miami, Florida, United States|Research Site, Pembroke Pines, Florida, United States|Research Site, Pompano Beach, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Buford, Georgia, United States|Research Site, Conyers, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Chicago, Illinois, United States|Research Site, Hazel Crest, Illinois, United States|Research Site, Noblesville, Indiana, United States|Research Site, West Des Moines, Iowa, United States|Research Site, Wichita, Kansas, United States|Research Site, Owensboro, Kentucky, United States|Research Site, Bethesda, Maryland, United States|Research Site, High Point, North Carolina, United States|Research Site, Wilmington, North Carolina, United States|Research Site, Orangeburg, South Carolina, United States|Research Site, Dallas, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Friendswood, Texas, United States|Research Site, Gonzales, Texas, United States|Research Site, Harlingen, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Riverton, Utah, United States|Research Site, Alexandria, Virginia, United States|Research Site, Portsmouth, Virginia, United States|Research Site, Richmond, Virginia, United States|Research Site, Tacoma, Washington, United States|Research Site, Bournemouth, United Kingdom|Research Site, Hayle, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Southampton, United Kingdom", ,https://ClinicalTrials.gov/show/NCT04625972
NCT04355741,"Gut Microbiota, ""Spark and Flame"" of COVID-19 Disease", ,Completed,No Results Available,COVID-19,Exposure,Differences in gut microbiota composition between COVID-19 patients with different degrees of disease severity.|Differences in gut microbiota composition between COVID-19 patients in relation to mortality.|Differences in gut microbiota composition between COVID-19 patients in relation to length of stay in hospitals.|Differences in gut microbiota composition between COVID-19 patients in relation to duration of mechanical ventilation.,"Universidade Nova de Lisboa|NOVA Medical School of Universidade NOVA de Lisboa|Hospital de São Francisco Xavier, Centro Hospitalar de Lisboa Ocidental|Centro Hospitalar Universitário São João|CUF Academic and Research Medical Center|Hospital CUF Infante Santo, S.A.|Centro de Medicina Laboratorial Germano de Sousa, S.A.|CINTESIS - Center for Health Technology and Services Research",All,18 Years, ,Adult|Older Adult, ,115,Other,Observational, ,Observational Model: Case-Only|Time Perspective: Cross-Sectional,COVID19_Microbiota,"April 20, 2020","July 1, 2020","July 16, 2020","April 21, 2020","August 25, 2020","Hospital CUF Infante Santo, S.A., Lisbon, Portugal|Hospital de São Francisco Xavier, Lisbon, Portugal|Centro Hospitalar Universitário São João, Oporto, Portugal", ,https://ClinicalTrials.gov/show/NCT04355741
NCT04388683,Inhaled Nitric Oxide for Preventing Progression in COVID-19,NO-COVID-19,Terminated,No Results Available,COVID-19,Nitric Oxide,"Prevention of progressive systemic de-oxygenation, with escalation to higher levels of oxygen and ventilatory support or death, assessed using a 7-point severity scale.|Prevention of progression assessed by an alternate severity scale|Time to reaching maximal severity score|Proportion of patients in each stage at maximum severity|PaO2/FIO2 or SaO2/FIO2 ratio, measured daily|Length of hospital Stay (death assigned as worst case)|Frequency of Intubation, ECMO, or need to intubate with ""Do Not Resuscitate"" order|Mortality|IL6 level|TNF-alpha level|Fibrinogen level|CRP level|Ferritin Level|D-dimer level",Tufts Medical Center|Bellerophon,All,18 Years,85 Years,Adult|Older Adult,Phase 2,10,Other|Industry,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,STUDY00000554,"May 12, 2020","November 23, 2020","November 23, 2020","May 14, 2020","September 30, 2021","Tufts Medical Center, Boston, Massachusetts, United States", ,https://ClinicalTrials.gov/show/NCT04388683
NCT04578158,Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19, ,Completed,No Results Available,COVID-19,Standard COVID-19 care|Quercetin Phytosome,Percentage of subjects with COVID-19 disease progression,Liaquat University of Medical & Health Sciences,All,18 Years, ,Adult|Older Adult,Phase 3,152,Other,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,LUMHS/REC/894,"September 29, 2020","March 28, 2021","April 15, 2021","October 8, 2020","April 22, 2021","Liaquat University Hospital, Jāmshoro, Sindh, Pakistan", ,https://ClinicalTrials.gov/show/NCT04578158
NCT04377763,Developement and Evaluation of Serological Assays for COVID-19,SEROCOV,Recruiting,No Results Available,COVID-19, ,Sensibility and specificity|Delay between the first symptoms and the positive serological result,Assistance Publique - Hôpitaux de Paris,All,18 Years, ,Adult|Older Adult, ,500,Other,Observational, ,Observational Model: Cohort|Time Perspective: Retrospective,20MWI-SEROCOV,"July 15, 2020",March 2021,March 2021,"May 6, 2020","February 25, 2021","Laboratory of microbiology of hospital hygiene, Ambroise Paré Hospital, APHP, Boulogne-Billancourt, France", ,https://ClinicalTrials.gov/show/NCT04377763
NCT04932941,MP1032 Treatment in Patients With Moderate to Severe COVID-19, ,Recruiting,No Results Available,COVID-19,MP1032|Placebo,"Percentage of Participants with Disease Progression at Day 14|Percentage of Participants with Disease Progression at Day 28|Percentage of Participants with Disease Resolution at Day 28|All-cause Mortality Rate at Day 28|Change from Baseline in Clinical Status related to COVID-19 according to the NIAID 8-point Ordinal Scale at Day 28|Percentage of Participants with Disease Resolution at Day 14|All-cause Mortality Rate at Day 14 and Day 60|Change from Baseline in Clinical Status related to COVID-19 According to the NIAID 8-point Ordinal Scale at Day 14|Percentage of Participants requiring Invasive Ventilation (Mechanical Ventilator and/or ECMO), or who are not Alive on Day 14 and Day 28|Percentage of Participants in each category of the NIAID 8-point Ordinal Scale|Time to (First) Improvement of at least 1 Category on the NIAID 8-point Ordinal Scale|The Odds Ratio for the Number of Participants with Clinical Status Improvement From Baseline on the NIAID 8-point Ordinal Scale at Day 14 and Day 28|Total Duration of Hospitalization at Day 28 and Day 60|Percentage of Participants alive and testing negative for COVID-19 at Day 14, Day 28, and Day 60|Number of Participants with treatment emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)|Number of Participants with Vital Sign Abnormalities|Number of Participants With Physical Examination Findings|Number of Participants with Laboratory Findings|Maximum Observed Plasma Concentration (Cmax) of MP1032|Area Under the Plasma Concentration-time curve from Time Zero (pre-dose) to last non-zero concentration (AUC0-t) of MP1032|Apparent Elimination Rate Constant (K) of MP1032|Apparent Body Clearance (CL) of MP1032|Apparent Volume of Distribution (Vd) of MP1032|Plasma Concentration Prior to the Next Dose (Ctrough) of MP1032|Average Observed Plasma Concentration at Steady State of MP1032","MetrioPharm AG|Syneos Health, LLC",All,18 Years, ,Adult|Older Adult,Phase 2,120,Industry|Other,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",MP1032-CT05|2021-000344-21,"October 19, 2021",April 2022,April 2022,"June 21, 2021","February 2, 2022","Snake River Research PLLC, Idaho Falls, Idaho, United States|Richmond University Medical Center, Staten Island, New York, United States|MHAT Dr. Stamen Iliev AD, Montana, Bulgaria|SHATPD Pernik EOOD, Pernik, Bulgaria|""Second Multiprofile Hospital For Active Treatment - Sofia"" Ead, Sofia, Bulgaria|Umhatem""N.I.Pirogov"", Sofia, Bulgaria|SHATPPD Sata Zagora EOOD, Stara Zagora, Bulgaria|Centre Hospitalier Victor Dupouy, Argenteuil, France|CHU de Grenoble Alpes, Grenoble Cedex 9, France|Centre Hospitalier Lyon Sud, Pierre-Benite CEDEX, France|DE KK Infektológiai Klinika, Debrecen, Hungary|Flor Ferenc Hospital of Pest County, Kistarcsa, Hungary|IRCCS Ospedale San Raffaele, Milan, Italy|Polo Universitario - L'Azienda Ospedaliera Luigi Sacco, Milan, Italy|Policlinico Agostino Gemelli, Roma, Italy|Spitalul Clinic de Boli Infectioase si Tropicale ""Dr. Victor Babes"", Bucharest, Romania|Spitalul Municipal Caracal, Caracal, Romania|Spitalul Clinic de Boli Infectioase ""Sfanta Parascheva"", Iaşi, Romania|Spitalul Judetean de Urgenta ""Sfantul Ioan cel Nou"", Suceava, Romania|Clinica Anestezie si Terapie Intensiva, Timişoara, Romania|Hospital Clinic de Barcelona Hospital Clinic i Provincial, Barcelona, Spain|Hospital Ramon y Cajal, Edificio Central, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla/IDIVAL, Santander, Spain|Hospital Universitario de Valme, Sevilla, Spain|Hospital Álvaro Cunqueiro, Vigo, Spain", ,https://ClinicalTrials.gov/show/NCT04932941
NCT04421534,Utility of Lactoferrin as an Adjunct Therapeutic Agent for COVID-19, ,Not yet recruiting,No Results Available,COVID-19,Lactoferrin,Time to clinical improvement|Rate of virological cure,Cairo University,All,18 Years,65 Years,Adult|Older Adult,Phase 2|Phase 3,150,Other,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,CUKA-001,June 2020,September 2020,November 2020,"June 9, 2020","June 9, 2020", , ,https://ClinicalTrials.gov/show/NCT04421534
NCT04501796,A Trial of NT-I7 in COVID-19 (SPESELPIS), ,Recruiting,No Results Available,COVID-19,Double-Blind NT-I7|Double-Blind Placebo,Evaluate the safety of a single dose of NT-I7 in a dose escalation fashion|Evaluate the immunological effects of NT-I7 cumulatively for all doses on peripheral lymphocyte counts in COVID-19 patients.,NeoImmuneTech|National Institute of Allergy and Infectious Diseases (NIAID)|University of Nebraska,All,19 Years,75 Years,Adult|Older Adult,Phase 1,30,Industry|NIH|Other,Interventional, ,"Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NIT-116 (SPESELPIS),"November 27, 2020",March 2022,June 2022,"August 6, 2020","December 13, 2021","Nih/Niaid, Bethesda, Maryland, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States", ,https://ClinicalTrials.gov/show/NCT04501796
NCT04428801,Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19, ,Not yet recruiting,No Results Available,COVID-19,autologous adipose-derived stem cells,"Tolerability and acute safety of AdMSC infusion by assessment of the total number of AEs/SAEs related and non-related with the medication|The overall proportion of subjects who develop any AEs/SAEs related and non-related with the AdMSC infusions as compared to the control group|COVID-19 incidence rates in both the study and control groups|The proportion of subjects who are infected by SARS-Cov-2 measured by PCR or other nuclear level-based SARS-Cov-2 virus testing in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method.|The proportion of subjects who are infected by SARS-Cov-2 virus develop symptoms including mild, classic, severe and critical sever cases between study group and control group.|Change of proportion of subjects who are infected by SARS-Cov-2 and develop IgM/IgG antibodies against SARS-Cov-2 between study group and control group.|Change of lymphocyte count in white blood cell counts from the baseline|Change of PaO2 arterial blood gases from the baseline|Compare the proportion of subjects who develop severe COVID-19 pneumonia cases for both study and control groups|COVID-19 mortality rates for both study and control groups|Change of C-reactive protein (CRP) (mg/L) from the baseline|Change of D-dimer (mg/L) from the baseline|Change of Procalcitonin (ug)/L from the baseline|Change of pro-type B natriuretic peptide (pro-BNP) (pg/mL) from the baseline|Change of Bilirubin (mg/dL) from the baseline|Change of Creatinine (mg/dL) from the baseline|Change in blood test values for cytokine panels (IL-1β, IL-6, IL-8, IL-10, TNFα) from the baseline|The proportion of subjects from SARS-CoV-2 RT-PCR positive to negativity in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method. as compared to control group|Quantifying viral RNA in stool for baseline and final follow-up.",Celltex Therapeutics Corporation,All,18 Years, ,Adult|Older Adult,Phase 2,200,Industry,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",CTX0020-003,September 2021,September 2022,September 2024,"June 11, 2020","July 23, 2021", , ,https://ClinicalTrials.gov/show/NCT04428801
NCT04625725,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.",PROVENT,"Active, not recruiting",No Results Available,COVID-19,AZD7442|Placebo,"The incidence of the first case of SARS CoV-2 RT PCR positive symptomatic illness|AEs, SAEs, MAAEs, and AESIs post dose of IMP|The incidence of participants who have a post-treatment response (negative at baseline to positive at any time post-baseline) for SARS-CoV-2 nucleocapsid antibodies.|The incidence of SARS-CoV-2 RT-PCR-positive severe or critical symptomatic illness occurring after dosing with IMP|The incidence of COVID-19-related Emergency Department visits occurring after dosing with IMP|Serum AZD7442 concentrations, PK parameters if data permit.|Incidence of ADA to AZD7442 in serum.",AstraZeneca|Iqvia Pty Ltd,All,18 Years,120 Years,Adult|Older Adult,Phase 3,5197,Industry,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",D8850C00002,"November 21, 2020","May 5, 2021","November 30, 2023","November 12, 2020","February 3, 2022","Research Site, Birmingham, Alabama, United States|Research Site, Tempe, Arizona, United States|Research Site, Little Rock, Arkansas, United States|Research Site, Cerritos, California, United States|Research Site, Fresno, California, United States|Research Site, Garden Grove, California, United States|Research Site, Huntington Beach, California, United States|Research Site, Lancaster, California, United States|Research Site, Modesto, California, United States|Research Site, Victorville, California, United States|Research Site, Westminster, California, United States|Research Site, Hartford, Connecticut, United States|Research Site, Middlebury, Connecticut, United States|Research Site, Clearwater, Florida, United States|Research Site, Coral Springs, Florida, United States|Research Site, Hollywood, Florida, United States|Research Site, Lauderdale Lakes, Florida, United States|Research Site, Miami, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Pompano Beach, Florida, United States|Research Site, Wesley Chapel, Florida, United States|Research Site, West Palm Beach, Florida, United States|Research Site, Atlanta, Georgia, United States|Research Site, Columbus, Georgia, United States|Research Site, Conyers, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Hazel Crest, Illinois, United States|Research Site, Quincy, Illinois, United States|Research Site, Evansville, Indiana, United States|Research Site, Noblesville, Indiana, United States|Research Site, Wichita, Kansas, United States|Research Site, Wichita, Kansas, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Minneapolis, Minnesota, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Omaha, Nebraska, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Bronx, New York, United States|Research Site, Jamaica, New York, United States|Research Site, Ridgewood, New York, United States|Research Site, Greensboro, North Carolina, United States|Research Site, Columbus, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Summerville, South Carolina, United States|Research Site, Rapid City, South Dakota, United States|Research Site, Austin, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, El Paso, Texas, United States|Research Site, Houston, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Shenandoah, Texas, United States|Research Site, Sugar Land, Texas, United States|Research Site, Layton, Utah, United States|Research Site, Alexandria, Virginia, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Alken, Belgium|Research Site, Bruxelles, Belgium|Research Site, Gozée, Belgium|Research Site, Namur, Belgium|Research Site, Wetteren, Belgium|Research Site, Clermont-Ferrand cedex, France|Research Site, Dijon cedex, France|Research Site, La Roche S/ Yon Cedex 9, France|Research Site, Lille, France|Research Site, Limoges cedex, France|Research Site, Nantes Cedex 1, France|Research Site, Paris cedex 10, France|Research Site, Paris cedex 14, France|Research Site, Saint Etienne Cedex 2, France|Research Site, Tours cedex 9, France|Research Site, Barcelona, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, Marbella (Málaga), Spain|Research Site, Pozuelo de Alarcón, Spain|Research Site, Bournemouth, United Kingdom|Research Site, Enfield, United Kingdom|Research Site, Hayle, United Kingdom|Research Site, London, United Kingdom|Research Site, Preston, United Kingdom|Research Site, Rochdale, United Kingdom|Research Site, Salford, United Kingdom|Research Site, Torpoint, United Kingdom|Research Site, Wakefield, United Kingdom", ,https://ClinicalTrials.gov/show/NCT04625725
NCT04466644,COVID-19: A Prevalence Study of Two ART Centres After the Pandemic Lockdown in the USA (COVID-19 Free Clinics), ,Completed,No Results Available,COVID-19,ELISA|RT-PCR,Prevalence of contagiousness in asymptomatic individuals by PCR with nasopharyngeal swabs|Ratio of asymptomatic immunized (IgG) population|To validate saliva specimens as a biological sample for COVID-19 testing,Igenomix,All,18 Years, ,Adult|Older Adult, ,340,Industry,Observational, ,Observational Model: Other|Time Perspective: Prospective,IGX2-COV-JC-20-04|20201490,"June 8, 2020","August 24, 2020","August 25, 2020","July 10, 2020","September 14, 2020","Boston IVF Fertility Clinic, Boston, Massachusetts, United States|Utah Fertility Clinic, Pleasant Grove, Utah, United States", ,https://ClinicalTrials.gov/show/NCT04466644
NCT04343183,Hyperbaric Oxygen Therapy (HBOT) as a Treatment for COVID-19 (COVID-19) Infection, ,Not yet recruiting,No Results Available,COVID-19,Hyperbaric Oxygen Therapy,Decrease incidence of intubation by 30% or greater|Decrease renal injury,Ochsner Health System,All,18 Years, ,Adult|Older Adult,Not Applicable,48,Other,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,STUDY00001051,April 2020,June 2020,June 2020,"April 13, 2020","April 13, 2020","Ochsner Medical Center, New Orleans, Louisiana, United States", ,https://ClinicalTrials.gov/show/NCT04343183
NCT04347915,The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19, ,Recruiting,No Results Available,COVID-19,Clevudine|Placebo,The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2)|The rate of subjects tested as negative SARS-Coronavirus-2 (SARS-CoV-2) in consecutive two days of Real-Time RT-PCR tests|The rate of subjects indicated by the improvement of lung invasive|The change of viral load,Bukwang Pharmaceutical,All,19 Years, ,Adult|Older Adult,Phase 2,60,Industry,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,BK-CLV-201,"May 6, 2020","January 30, 2021","March 31, 2021","April 15, 2020","January 27, 2021","Korea University Guro Hospital, Seoul, Korea, Republic of", ,https://ClinicalTrials.gov/show/NCT04347915
NCT04470622,Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1), ,Terminated,No Results Available,COVID-19,Aprepitant injectable emulsion|Saline Placebo,"Proportion of subjects alive and discharged from the hospital.|Time to death or respiratory failure, defined as any of the following: endotracheal intubation and mechanical ventilation; oxygen delivered by high-flow nasal cannula; noninvasive positive pressure ventilation; extracorporeal membrane oxygenation (ECMO).|Time to discharge from hospital.|Change from Baseline in Interleukin 6 (IL-6).|Incidence of treatment-emergent adverse events.",Heron Therapeutics,All,18 Years, ,Adult|Older Adult,Phase 2,27,Industry,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HTX-019-202,"July 20, 2020","April 9, 2021","June 3, 2021","July 14, 2020","October 20, 2021","Helen Keller Hospital, Sheffield, Alabama, United States|University of California, Irvine Medical Center, Orange, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States", ,https://ClinicalTrials.gov/show/NCT04470622
NCT04610554,Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide Early After Mild-to-severe COVID-19, ,Completed,No Results Available,COVID-19 Pneumonia, ,Lung diffusing capacity for nitric oxide (DLNO)|Lung diffusing capacity for carbon monoxide (DLco),"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",All, , ,Child|Adult|Older Adult, ,74,Other,Observational, ,Observational Model: Cohort|Time Perspective: Cross-Sectional,SARS-CoV-2_DLNO,"May 14, 2020","October 12, 2020","October 12, 2020","October 30, 2020","October 30, 2020","IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy", ,https://ClinicalTrials.gov/show/NCT04610554
NCT04889040,Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19,MORNINGSKY,Terminated,No Results Available,COVID-19,RO7496998|Placebo,"Time to Alleviation or Improvement of COVID-19 Symptoms (21.5 hours)|Time to Alleviation or Improvement of COVID-19 Symptoms (43 hours)|Time to Alleviation of COVID-19 Symptoms (21.5 hours)|Time to Alleviation of COVID-19 Symptoms (43 hours)|Time to One-Category Improvement of Baseline Presenting COVID-19 Symptoms|Time to Alleviation of Individual Symptoms|Proportion of Participants Requiring Hospitalization for COVID-19|Proportion of Participants with Greater than or Equal to 1 COVID-19 Related Medically Attended Visit|Duration of Fever|Frequency of COVID-19 Related Complications|Proportion of Participants with any Post-Treatment Infection|Change from Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA|Time to Cessation of SARS-CoV-2 Viral Shedding|Proportion of Participants Positive for SARS-CoV-2 Virus RNA at Specified Timepoints|Area Under the Curve (AUC) in the Amount of SARS-CoV-2 Virus RNA|Percentage of Participants with Adverse Events (AEs)|Plasma Concentration of AT-511, AT-551, AT-229 and AT-273 at Specified Timepoints","Hoffmann-La Roche|Atea Pharmaceuticals, Inc.",All,12 Years, ,Child|Adult|Older Adult,Phase 3,1386,Industry,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",CV43043|2020-005759-18,"April 28, 2021","November 17, 2021","November 17, 2021","May 17, 2021","February 4, 2022","Instituto Medico Rio Cuarto, Cordoba, Argentina|Instituto Ave Pulmo, Mar Del Plata, Argentina|Clínica Independencia, Munro, Argentina|Instituto Medico de la Fundacion Estudios Clinicos, Rosario, Argentina|Clinica Mayo de U.M.C.B. S.R.L, San Miguel de Tucumán, Argentina|Sanatorio Medico de Diagnostico Y Tratamiento, Santa Fe, Argentina|Maison Médicale La Brèche, Châtelineau, Belgium|Private Practice Dr Jean Benoit Martinot, Erpent, Belgium|Medif, Gozée, Belgium|L2 Ip Instituto de Pesquisas Clinicas Ltda ME; Centro Medico Hospitalar, Brasilia, DF, Brazil|Chronos Pesquisa Clinica, Taguatinga, DF, Brazil|Hospital das Clinicas - UFMG, Belo Horizonte, MG, Brazil|Hospital Agamenon Magalhães, Recife, PE, Brazil|Hospital Nossa Senhora das Graças, Curitiba, PR, Brazil|Hospital Erasto Gaertner, Curitiba, PR, Brazil|Hospital E Maternidade Celso Pierro PUCCAMP, Campinas, SP, Brazil|Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS, Sao Jose Do Rio Preto, SP, Brazil|CPQuali Pesquisa Clínica Sao Paulo, Sao Paulo, SP, Brazil|Institute of Infectious Diseases Emilio Ribas, Sao Paulo, SP, Brazil|Conjunto Hospitalar do Mandaqui, Sao Paulo, SP, Brazil|Healthy Medical Center SAS, Zipaquirá, Colombia|Aalborg Universitetshospital, Aalborg, Denmark|Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark|Sjællands Universitetshospital, Roskilde, Roskilde, Denmark|Centre Hospitalier Victor Dupouy, Argenteuil, France|Hôpital Saint Joseph, Marseille, France|Hopital Tenon, Paris, France|Klinikum Chemnitz gGmbH, Chemnitz, Germany|Universitätsklinikum Frankfurt, Frankfurt, Germany|Universitätsklinikum Freiburg, Freiburg, Germany|Praxis am Ebertplatz, Köln, Germany|ASST di Lecco - Presidio Ospedaliero A. Manzoni di Lecco, Lecco, Lombardia, Italy|Ospedale San Raffaele S.r.l., Milano, Lombardia, Italy|Comprensorio Amedeo Di Savoia Birago Di Vische, Torino, Piemonte, Italy|Funabashi Central Hospital, Funabashi-Shi, Japan|Higashiosaka city Medical Center, Higashiosaka-Shi, Japan|Rinku General Medical Center, Izumisano, Japan|Sagamihara Kyodo Hospital, Kanagawa, Japan|Misyuku hospital, Meguro-Ku, Japan|Nagoya City East Medical Center, Nagoya-Shi Chikusa-Ku, Japan|Fujita Health University Banbuntane Hotokukai Hospital, Nagoya-shi, Japan|Tokyo Metropolitan Police Hospital, Nakano-Ku, Japan|IUHW Narita Hospital, Narita, Japan|Houjin Syadan Kouhoukai Takagi Hospital, Okawa-Shi, Japan|Okayama City Hospital, Okayama, Japan|Ome Municipal General Hospital, Ome-Shi, Japan|Osaka City General Hospital, Osaka, Japan|National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai-shi, Japan|Tokyo Shinagawa Hospital Medical Corporation Association Tokyokyojuno-kai, Shinagawa, Japan|St. Luke's International Hospital, Tokyo, Japan|Edogawa Medicare Hospital, Tokyo, Japan|Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan|JCHO Tokyo Shinjuku Medical Center, Tokyo, Japan|Tokyo Medical University Hachioji Medical Center, Tokyo, Japan|National Hospital Organization Kasumigaura Medical Center, Tsuchiurat, Japan|Mie Prefectural Medical Centre, Yokkaichi, Japan|CIMAB SA de CV, Torreón, Coahuila, Mexico|Panamerican Clinical Research S.A de C.V., Guadalajara, Jalisco, Mexico|Clinstile S.A de C.V., Mexico City, Mexico CITY (federal District), Mexico|PanAmerican Clinical Research, Querétaro, Queréaro, Queretaro, Mexico|Instituto Jalisciense de Investigacion Clinica S.A. de C.V., Guadalajara, Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico, Mexico|CEPREP; Hospital Universitario, Monterrey, Mexico|Hospital Senhora da Oliveira - Guimaraes, E.P.E, Guimarães, Portugal|Centro Hospitalar de Leiria (CHL), Leiria, Portugal|Unidade Local de Saude de Matosinhos SA, Matosinhos, Portugal|Prof. Dr. Matei Bals Institute of Infectious Diseases, Bucuresti, Romania|County Hospital Caracal, Caracal, Romania|Sibiu Emergency Clinical County Hospital, Sibiu, Romania|Dr. Victor Babes Clinical Hospital of Pneumophthisiology and Infectious Diseases, Timişoara, Romania|Dr JM Engelbrecht Trial site, Cape Town, South Africa|TASK Eden, George, South Africa|Langeberg Clinical Trials, Kraaifontein, South Africa|Clinical Projects Research, Worcester, South Africa|Hôpital Universitaire de Genève (HUG), Genève, Switzerland|Universitätsspital Zürich, Zürich, Switzerland|Gazi Universitesi Tip Fakultesi, Ankara, Turkey|Hacettepe University Medical Faculty, Ankara, Turkey|Koc University Medical Faculty Hospital, Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Karadeniz Technical University Faculty of Medicine, Trabzon, Turkey|Ankara University Medical Faculty - PPDS, Çankaya, Turkey|Istanbul University Cerrahpasa Medical Faculty Hospital; Tesvikiye Caddesi No:20, Şi̇şli̇, Turkey|Municipal Non-profit enterprise Central City Clinical Hospital of Ivano-Frankivsk City Council, Ivano-Frankivsk, Katerynoslav Governorate, Ukraine|Municipal Non-profit Enterprise ""City Clinical Hospital #13"" of Kharkiv City Council, Kharkiv, Kharkiv Governorate, Ukraine|Public Non-Profit Enterprise ""City Outpatient Clinic #9"" of Kharkiv City Council, Kharkiv, Kharkiv Governorate, Ukraine|CNPE City Clinical Hospital #6 of DCC, Dnipro, Kholm Governorate, Ukraine|Municipal Non-profit Enterprise ""City Clinical Hospital # 4"" of Dnipro City Council, Dnipro, KIEV Governorate, Ukraine|CNPE Ivano-Frankivsk Regional Centre of Phthisiology and Pulmonology of IFRC, Ivano Frankivsk, KIEV Governorate, Ukraine|Private Enterprise Private Manufacture Company ""Acinus"", diagnostic and treatment center, Kirovograd, KIEV Governorate, Ukraine|Medical Center LLC ""Harmony of Beauty"", Kyiv, KIEV Governorate, Ukraine|CNE Kyiv City Clinical Hospital#1 of Exec. Body, Kyiv, KIEV Governorate, Ukraine|Medical Center of LLC Preventclinic, Kyiv, KIEV Governorate, Ukraine|Kyiv Railway Clinical Hospital No2 of Branch Health Center of the JSC Ukrainian Rail, Kyiv, KIEV Governorate, Ukraine|Polyclinic of Center of Medical Service and Rehabilitation of State JSHC Artem, Kyiv, KIEV Governorate, Ukraine|Communal Non-Commercial Enterprise Vinnytsia City Clinical Hospital 1, Vinnytsya, Podolia Governorate, Ukraine|Communal Non-Profit Enterprise City Hospital #7 of Zaporizhzhia City Council, Zaporizhzhia, Tavria Okruha, Ukraine", ,https://ClinicalTrials.gov/show/NCT04889040
NCT04331509,COVID-19 Symptom Tracker, ,Recruiting,No Results Available,COVID-19,No Intervention,Physical health symptoms|Lack of physical health symptoms|Fever,King's College London|Zoe Global Limited|Massachusetts General Hospital|Harvard School of Public Health (HSPH)|Stanford University,All,18 Years, ,Adult|Older Adult, ,10000000,Other,Observational, ,Observational Model: Cohort|Time Perspective: Prospective,COVID-19 Symptom tracker,"March 23, 2020","March 23, 2022","March 23, 2022","April 2, 2020","April 7, 2020","Massachusetts General Hospital, Boston, Massachusetts, United States|King's College London, London, United Kingdom", ,https://ClinicalTrials.gov/show/NCT04331509
NCT04742569,Wearable Diagnostic for Detection of COVID-19 Infection, ,Completed,No Results Available,COVID-19, ,"The primary outcome of interest are performance of the BioSticker, a medical grade multi-parameter wearable biosensor.|The primary outcome of interest are performance of the BioSticker wearable for detecting early onset of active COVID-19 related symptoms.|The primary outcome of interest is the sensitivity of the BioCloud-based algorithms in detecting early onset of active COVID-19.|The secondary outcomes of interest include correlation of biometric data indicators to patient reported symptoms.","ClinOne, Inc.|BioIntelliSense, Inc|Phillips North America, LLC|University of Colorado, Denver|United States Department of Defense",All,18 Years, ,Adult|Older Adult, ,790,Industry|Other|U.S. Fed,Observational, ,Observational Model: Cohort|Time Perspective: Prospective,1294415,"December 21, 2020","January 15, 2022","January 15, 2022","February 8, 2021","January 20, 2022","ClinOne, Inc, Greenwood Village, Colorado, United States", ,https://ClinicalTrials.gov/show/NCT04742569
NCT05197153,"A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19", ,Not yet recruiting,No Results Available,COVID-19 Vaccine,Half dose of MVC-COV1901|Full dose of MVC-COV1901|AZD1222|Half dose of mRNA-1273,Incidence of Adverse Events from Day 1 to 28|Primary Immunogenicity-1|Primary Immunogenicity-2|Primary Immunogenicity-3|Primary Immunogenicity-4|Incidence of Adverse Events from Day 1 to 181|Secondary Immunogenicity (Humoral)-1|Secondary Immunogenicity (Humoral)-2|Secondary Immunogenicity (Humoral)-3|Secondary Immunogenicity (Cellular),Medigen Vaccine Biologics Corp.|Coalition for Epidemic Preparedness Innovations,All,18 Years,80 Years,Adult|Older Adult,Phase 2,960,Industry|Other,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention",CT-COV-24,January 2022,April 2022,December 2022,"January 19, 2022","January 19, 2022","Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Municipal Wan Fang Hospital, Taipei, Taiwan|Taipei Veteran General Hospital, Taipei, Taiwan", ,https://ClinicalTrials.gov/show/NCT05197153
NCT04523090,Catalysing the Containment of COVID-19,C3-RCT,Recruiting,No Results Available,COVID-19,Nitazoxanide|Placebo,"Time specific disease severity|Progression to severe disease|Need for respiratory support (high flow nasal oxygen, non-invasive ventilation, or intubation) in those admitted to hospital because of disease progression.|In-hospital and 30- and 60-day all-cause mortality.|Time-specific viral load as measured by RT-PCR using NP swabs and sputum (where available).|Cough aerosol sampling positivity|Duration and severity of symptoms.|Time-specific antibody titres (IgG and IgM).|COVID-19 incidence rates in contacts.|Adverse events","University of Cape Town|Medical Research Council, South Africa|Aurum Institute|National Institutes of Health (NIH)|Texas Tech University Health Sciences Center|University of KwaZulu|Perinatal HIV Research Unit of the University of the Witswatersrand",All,18 Years,120 Years,Adult|Older Adult,Phase 2|Phase 3,440,Other|NIH,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",C3-RCT,"August 27, 2020",December 2021,February 2022,"August 21, 2020","June 7, 2021","The Aurum Institute, Tembisa, Gauteng, South Africa|University of KwaZulu-Natal, Durban, KwaZulu-Natal, South Africa|Perinatal HIV Research Unit, Klerksdorp, North West, South Africa|University of Cape Town, Cape Town, Western Cape, South Africa", ,https://ClinicalTrials.gov/show/NCT04523090
NCT05195736,Predicting COVID-19 Patients' Clinical Outcomes Using ICU Mobility Scale and MRC Sum Score, ,Completed,No Results Available,COVID-19, ,Barthel index|Hospitalization days,Taichung Veterans General Hospital,All, , ,Child|Adult|Older Adult, ,33,Other,Observational, ,Observational Model: Cohort|Time Perspective: Retrospective,CE21317A#1,"September 16, 2021","December 31, 2021","December 31, 2021","January 19, 2022","February 3, 2022","Taichung Veterans General Hospital, Taichung, Republic Of China(R.O.C), Taiwan", ,https://ClinicalTrials.gov/show/NCT05195736
NCT04452669,VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation,VPCOVID,Completed,No Results Available,COVID-19,VentaProst (inhaled epoprostenol delivered via a dedicated delivery system),Reduction in Respiratory Failure|Reduction in Cardiac/Circulatory Failure|Improvement in Oxygenation|Improved Clinical Outcomes,Aerogen Pharma Limited|Ohio State University,All,18 Years, ,Adult|Older Adult,Phase 2,11,Industry|Other,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",APC-VPCOV-CLN-001,"September 15, 2020","June 29, 2021","June 29, 2021","June 30, 2020","August 5, 2021","Ohio State University, Columbus, Ohio, United States", ,https://ClinicalTrials.gov/show/NCT04452669
NCT04854928,Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection., ,Recruiting,No Results Available,COVID-19,"LTX-109 gel, 3%|Placebo gel",Reduction in Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2 ) viral load in the deep nasal cavity as measured by the amount of live virus in the samples.|Reduction in SARS-CoV-2 viral load in the anterior nasal cavity as measured by the amount of live virus in the samples.|Assessment of safety and tolerability by frequency and seriousness of Adverse Events (AE)|Assessment of safety and tolerability by intensity of AE,Pharma Holdings AS|CTC Clinical Trial Consultants AB,All,18 Years, ,Adult|Older Adult,Phase 2,60,Industry,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",C21-109-09,"May 3, 2021",February 2022,May 2022,"April 22, 2021","September 20, 2021","ClinSmart Sweden AB, Uppsala, Sweden", ,https://ClinicalTrials.gov/show/NCT04854928
NCT04406389,Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial),IMPACT,Recruiting,No Results Available,COVID-19,Enoxaparin sodium|Unfractionated heparin|Fondapariniux|Argatroban,"30-day mortality|Length of Intensive Care Unit (ICU) Stay in Days|Number of documented venous thromboembolism (VTE), arterial thrombosis (stroke, myocardial infarction, other) and microthrombosis events|Number of major and clinically relevant non-major bleeding events",Weill Medical College of Cornell University,All,18 Years, ,Adult|Older Adult,Phase 4,186,Other,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,20-04021936,"October 13, 2020",June 2022,December 2022,"May 28, 2020","August 2, 2021","Weill Cornell Medicine, New York, New York, United States", ,https://ClinicalTrials.gov/show/NCT04406389
NCT04291053,The Efficacy and Safety of Huai er in the Adjuvant Treatment of COVID-19, ,Not yet recruiting,No Results Available,COVID-19,Huaier Granule,Mortality rate|Clinical status assessed according to the official guideline|The differences in oxygen intake methods|Duration (days) of supplemental oxygenation|Duration (days) of mechanical ventilation|The mean PaO2/FiO2|Length of hospital stay (days)|Length of ICU stay (days)|Pulmonary function,Tongji Hospital,All,18 Years,75 Years,Adult|Older Adult,Phase 2|Phase 3,550,Other,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,TJ-IRB20200205,"April 1, 2020","August 1, 2020","September 1, 2020","March 2, 2020","March 17, 2020", , ,https://ClinicalTrials.gov/show/NCT04291053
NCT04842435,Clinical Study in the Treatment of Patients With Moderate Course of COVID-19, ,Recruiting,No Results Available,COVID-19,COVID-globulin|Placebo,"The proportion of subjects in the study groups in whom, during the first 7 days after drug administration, one of the following events developed according to the laboratory-instrumental methods or on the basis of a clinical presentation|All-cause mortality|The elimination time of the SARS-CoV-2 virus|The median time to clinical improvement on the WHO Ordinal Scale for Clinical Improvement|The incidence of severe and extremely severe COVID-19 disease|The need for respiratory support|The need for invasive mechanical ventilation of the lungs, ECMO|Time to cancellation of oxygen support|The need to stay at the intensive care unit|Duration of fever (≥ 380C), days|The dynamics of the decrease in points on the NEWS scale|Dynamical CRP, ferritin, D-dimer values|Changes in the degree of lung lesion determined by the CT",Microgen,All,18 Years,65 Years,Adult|Older Adult,Phase 2|Phase 3,376,Other,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",IGK-P-II/III-00-003/2020,"April 12, 2021","September 30, 2021","October 5, 2021","April 13, 2021","May 14, 2021","15. Municipal Autonomous Institution ""Central City Clinical Hospital No. 24"", Ekaterinburg, Russian Federation|9. State Autonomous Healthcare Institution ""Professor A. F. Agafonov Republican Clinical Infectious Hospital"", Kazan, Russian Federation|13. State Budgetary Healthcare Institution ""Specialized Clinical Infectious Diseases Hospital"" of the Ministry of Health of the Krasnodar Territory, Krasnodar, Russian Federation|6. State Budgetary Healthcare Institution ""Scientific and Research Institute Professor S. V. Ochapovskiy Territorial Clinical Hospital"" of the Ministry of Health of the Krasnodar Territory, Krasnodar, Russian Federation|1. State Budgetary Institution of Healthcare of Moscow ""City Clinical Hospital No. 40 of the Moscow Department of Health"", Moscow, Russian Federation|14. State Budgetary Institution of Healthcare of Moscow ""Infectious Clinical Hospital No. 2"" of the Moscow Department of Health, Moscow, Russian Federation|16. State Budgetary Institution of Healthcare of Moscow ""Infectious Clinical Hospital No. 1"" of the Moscow Department of Health, Moscow, Russian Federation|18. State Budgetary Institution of Healthcare of Moscow ""City Clinical Hospital No. 52 of the Moscow Department of Health"", Moscow, Russian Federation|19. State Budgetary Institution of Healthcare of Moscow ""City Clinical Hospital of V.P. Demikhova of the Moscow Department of Health"", Moscow, Russian Federation|20. State Budgetary Institution of Healthcare of Moscow ""Scientific and Research Institute of N.V. Sklifosovskiy of the Moscow Department of Health"", Moscow, Russian Federation|21. State Budgetary Institution of Healthcare of Moscow ""City Clinical Hospital No. 4 of the Moscow Department of Health"", Moscow, Russian Federation|3. State Budgetary Healthcare Institution of Moscow ""City Clinical Hospital No. 24 of the Moscow Department of Health"", Moscow, Russian Federation|7. Federal State Budgetary Institution ""Central Clinical Hospital with an Outpatient Facility"" of the Administrative Directorate of the President of the Russian Federation, Moscow, Russian Federation|4. Federal State Budgetary Educational Institution of Higher Education ""Orenburg State Medical University"" of the Ministry of Health of the Russian Federation, Orenburg, Russian Federation|10. Federal State Budgetary Educational Institution of Higher Education ""Academician I. P. Pavlov Ryazan State Medical University"" of the Ministry of Health of the Russian Federation, Ryazan', Russian Federation|5. Saint Petersburg State Budgetary Healthcare Institution ""City Hospital No. 40 of the Kurortny Region"", Saint Petersburg, Russian Federation|12. Federal State Budgetary Educational Institution of Higher Education ""Samara State Medical University"" of the Ministry of Health of the Russian Federation, Samara, Russian Federation|11. Regional State Budgetary Healthcare Institution ""Clinical Hospital No. 1"", Smolensk, Russian Federation|17. Federal State Budgetary Educational Institution of Higher Education ""Bashkiria State Medical University"" of the Ministry of Health of the Russian Federation, Ufa, Russian Federation|8. State Budgetary Healthcare Institution of the Yaroslavl Region ""Yaroslavl Regional Clinical Hospital of War Veterans - International Center for Problems of the Elderly ""Zdorovoye Dolgoletiye"", Yaroslavl, Russian Federation|2. State Budgetary Institution of Healthcare of the Moscow Region ""Zhukovskiy City Clinical Hospital"", Zhukovskiy, Russian Federation", ,https://ClinicalTrials.gov/show/NCT04842435
NCT04780672,Clinical Study in the Treatment of Patients With COVID-19, ,Recruiting,No Results Available,COVID-19,Molixan|Placebo,WHO Ordinal Scale for Clinical Improvement|Mortality|Duration of hospitalization|Mechanical ventilation|Time to cancellation of oxygen support|Invasive mechanical ventilation|Stay in the intensive care unit|The transition of the disease to an extremely severe course|Fever|The dynamics of the National Early Warning Score (NEWS)|The dynamics of changes in the level of C-reactive protein|The dynamics of residual symptoms|The dynamics of blood biochemical parameters|The dynamics of CT signs,Pharma VAM,All,18 Years,75 Years,Adult|Older Adult,Phase 3,330,Other,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",MNCV-III/2-2020,"March 9, 2021","May 31, 2022","September 30, 2022","March 3, 2021","October 11, 2021","Yaroslavl Regional Clinical Hospital for War Veterans - The International Center for the Elderly ""Healthy Longevity"", Yaroslavl, Russian Federation", ,https://ClinicalTrials.gov/show/NCT04780672
NCT04342637,COVID-19 Endoscopy Survey,COVID-19 Endo,Completed,No Results Available,COVID-19,Practice details,Effect of GI societies recommendations on prevention of SARS-CoV-2 infection|To measure the percentage change in performed endoscopic procedure in response to COVID-19|Effect of COVID-19 precautions on procedure time|Effect of COVID-19 precautions on time of disinfection|Effect of COVID-19 precautions on procedure success|Effect of COVID-19 precautions on complications|Effect of COVID-19 precautions on working time|Effect of COVID-19 precautions on staff number,Al-Azhar University,All,30 Years,70 Years,Adult|Older Adult, ,163,Other,Observational, ,Observational Model: Cohort|Time Perspective: Prospective,WES-2,"April 10, 2020","April 25, 2020","May 1, 2020","April 13, 2020","May 20, 2020","Kings County Hospital Center, Brooklyn, NY, USA, Albertson, New York, United States|Faculty of Medicine, Zagazig University, Zagazig, Sharkia, Egypt|Al-Azhar Univerisity, Cairo, Egypt|Ahvaz Imam hospital, Ahvaz, Iran, Islamic Republic of", ,https://ClinicalTrials.gov/show/NCT04342637
NCT04412486,COVID-19 Convalescent Plasma (CCP) Transfusion, ,Recruiting,No Results Available,COVID-19,COVID Convalescent Plasma,Change in PaO2/FiO2 after CCP transfusion.|Change in pulse oximetry status after CCP transfusion.|Change in aO2 after CCP transfusion.|Change in respiratory rate after CCP transfusion.|Change in intubation status after CCP transfusion.|Change in Sequential Organ Failure Assessment (SOFA).|Change in 8-point ordinal clinical deterioration scale.|Length of ICU/hospital stay.|Development of plasma transfusion reactions.|Development of immune complex disorders.|Change in anti CoV-2 IgM and IgG levels.,"Gailen D. Marshall Jr., MD PhD|University of Mississippi Medical Center",All,18 Years, ,Adult|Older Adult,Early Phase 1,100,Other,Interventional, ,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,2020-0137,"June 1, 2020","May 31, 2022","May 31, 2022","June 2, 2020","December 1, 2021","University of Mississippi Medical Center, Jackson, Mississippi, United States", ,https://ClinicalTrials.gov/show/NCT04412486
NCT05075915,Transfusion and COVID-19,TRANSCOV-19,Recruiting,No Results Available,COVID-19, ,"Study of the consumption of labile blood products at Strasbourg University Hospitals, during the two covid-19 periods: from February 24 to May 31, 2019 and 2020","University Hospital, Strasbourg, France",All,18 Years, ,Adult|Older Adult, ,500,Other,Observational, ,Observational Model: Case-Only|Time Perspective: Retrospective,7958,"September 1, 2020","December 31, 2021","December 31, 2021","October 13, 2021","December 1, 2021","Service d'Anesthésie et Réanimation chirurgicale - Hôpitaux Universitaires de Strasbourg, Strasbourg, France", ,https://ClinicalTrials.gov/show/NCT05075915
NCT05157217,Impact of the Genetic Polymorphism on COVID-19 in Egypt, ,Not yet recruiting,No Results Available,COVID-19, ,"ACE I/D gene polymorphism (rs4343)|Angiotensin-converting enzyme 2 (ACE2) gene polymorphism (rs908004)|Type 2 transmembrane serine protease (TMPRSS2) gene polymorphism (rs12329760)|Potential interaction between ACE (I/D), ACE2 and TMPRSS2 gene polymorphisms and the occurrences of severe complications in patients with COVID-19 disease.1",Cairo University|Misr International University,All,18 Years,80 Years,Adult|Older Adult, ,98,Other,Observational, ,Observational Model: Case-Control|Time Perspective: Other,N-134-2020,December 2021,February 2022,March 2022,"December 14, 2021","December 14, 2021","Cairo University Hospitals, Cairo, Egypt", ,https://ClinicalTrials.gov/show/NCT05157217
NCT05184127,Evaluation of Safety & Efficacy of MIR 19 ® Inhalation Solution in Patients With Moderate COVID-19, ,Completed,No Results Available,COVID-19,MIR 19 ®|Standard COVID-19 therapy,Relief of fever|Respiratory rate|Oxygen saturation|Severity of cough,National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia|St. Petersburg Research Institute of Vaccines and Sera,All,18 Years,65 Years,Adult|Older Adult,Phase 2,156,Other,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,SiCoV/KK46- 2021_CSR,"April 27, 2021","September 7, 2021","September 7, 2021","January 11, 2022","January 11, 2022","NRC Institute of Immunology FMBA, Moscow, Russian Federation", ,https://ClinicalTrials.gov/show/NCT05184127
NCT04747769,COVID-19. CT-Scan Modeling in COVID19 Sequelae,SILICOVILUNG,Recruiting,No Results Available,COVID-19, ,Qualitative and quantitative parameters obtained by in silico modeling of intra-pulmonary vascular remodeling in 3D at 2-4 months.|Specific mechanical parameters of pulmonary parenchymal stiffness/localized compliances obtained by dynamic poromechanical modeling at 2-4 months.,Assistance Publique - Hôpitaux de Paris,All,18 Years, ,Adult|Older Adult, ,50,Other,Observational, ,Observational Model: Case-Only|Time Perspective: Retrospective,APHP210006,"February 3, 2021","October 1, 2021",October 2021,"February 10, 2021","August 30, 2021","Hôpital Avicenne APHP, Bobigny, France", ,https://ClinicalTrials.gov/show/NCT04747769
NCT04552366,A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults, ,"Active, not recruiting",No Results Available,COVID-19,Ad5-nCoV,Incidence of the AE in all groups|Seroconversion rate of the IgG antibody against SARS-CoV-2|Geomean titers of the IgG antibody against SARS-CoV-2|Seroconversion rate of the neutralizing antibody against SARS-CoV-2|Geomean titers of the neutralizing antibody against SARS-CoV-2|Incidence of Serious adverse events (SAE) in all groups|Cellular immune response by ELISpot|Geomean titers of neutralizing antibody response to Ad5-vector|Cellular immune response by ICS|Geomean titers of the IgA antibody against SARS-CoV-2,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China|Zhongnan Hospital",All,18 Years, ,Adult|Older Adult,Phase 1,149,Other,Interventional, ,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,AMMS85-2004,"September 29, 2020","December 31, 2020","June 30, 2021","September 17, 2020","December 7, 2020","Zhongnan Hospital, Wuhan, Hubei, China", ,https://ClinicalTrials.gov/show/NCT04552366
NCT04336462,Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19,COVID-19,Recruiting,No Results Available,COVID-19,oxyhydrogen|Oxygen,Recovery time|Clinical Symptom Remission time|fever duration|Leicester cough questionaire (LCQ)|minimum oxygen|Negative conversion rate|white blood cell(WBC)|Red blood cells(RBC)|Hemoglobin(Hb )|Platelets(PLT)|Lymphocyte count|The percentage of lymphocyte|neutrophils|C-reactive protein (CRP)|Myocardial enzyme|liver function|Renal function|Muscle enzyme,"Shanghai Asclepius Meditec Inc.|Shanghai Public Health Clinical Center|Henan Provincial People's Hospital|Shenzhen Third People's Hospital|The First People's Hospital of Yunnan|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Shanghai 6th People's Hospital|Guangdong Provincial Hospital of Traditional Chinese Medicine",All,18 Years,85 Years,Adult|Older Adult,Not Applicable,100,Industry|Other,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",JT202002LZ,"February 15, 2020","February 21, 2020","August 1, 2020","April 7, 2020","April 7, 2020","First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China", ,https://ClinicalTrials.gov/show/NCT04336462
NCT04534673,Pegylated Interferon Lambda for Treatment of COVID-19 Infection, ,Recruiting,No Results Available,COVID-19,Lambda 180 mcg S.C,Viral shedding in days since initial diagnosis|Rate of adverse events and severe adverse events|Time to clinical recovery|Rate of non-invasive or mechanical ventilation|Length of hospital stay|All-cause mortality|Undetectable COVID-19 virus levels,Soroka University Medical Center,All,18 Years, ,Adult|Older Adult,Phase 2,40,Other,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,0129-20-SOR|SCRC200006,"April 7, 2020","December 31, 2023","December 31, 2024","September 1, 2020","January 28, 2022","Soroka UMC, Be'er Sheva, Israel", ,https://ClinicalTrials.gov/show/NCT04534673
NCT04770467,"A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19", ,Withdrawn,No Results Available,COVID-19,BRII-196 and BRII-198|Placebo,Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Change from pre-dose baseline in RBC count|Change from pre-dose baseline in WBC count|Change from pre-dose baseline in Platelets count|Change from pre-dose baseline in Hemoglobin result|Change from pre-dose baseline in Creatine kinase result|Change from pre-dose baseline in Alanine aminotransferase (ALT) result|Time-weighted average changes in SARSCoV-2 RNA levels in nasopharyngeal swabs from baseline to Day 8|Duration of COVID-19 related symptoms through Day 29 among subjects with mild-moderate COVID-19|Proportion of subjects who have mild-moderate COVID-19 and develop severe COVID-19 after randomization|Assessment of PK parameters: maximum serum concentration observed (Cmax),"Brii Biosciences, Inc.|Brii Biosciences Limited",All,18 Years, ,Adult|Older Adult,Phase 2,0,Industry,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,BRII-196-198-002,February 2021,October 2022,October 2022,"February 25, 2021","June 7, 2021","Investigative Site 1, Hong Kong, China", ,https://ClinicalTrials.gov/show/NCT04770467
NCT04928430,Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19, ,Recruiting,No Results Available,COVID-19,XAV-19|Placebo,Proportion of patients with an aggravation of COVID-19|Change in Clinical parameters : body temperature|Change in Clinical parameters : Respiratory rate|Change in Clinical parameters : SpO2 at ambiant air|Change in Clinical parameters : Supplemental O2|Change in severity on Common Terminology Criteria of Adverse Events (CTCAE) scale (version 5.0)|Duration of patient's requirement in supplemental O2|Duration of aggravation|Length of hospital stay|Viral status: RT-PCR or RT-qPCR for SARS-CoV-2|Proportion of patients referred to Intensive Care Unit (ICU)|Proportion of patients with need for mechanical ventilation|Survival rates|Safety: Occurrence of adverse effects|Safety: hypersensitivity or allergy|Safety: laboratories abnormalities : white blood cell count|Safety: laboratories abnormalities : red blood cell count|Safety: laboratories abnormalities : hemoglobin|Safety: laboratories abnormalities : platelets|Safety: laboratories abnormalities : creatinine,Xenothera SAS,All,18 Years, ,Adult|Older Adult,Phase 2|Phase 3,722,Industry,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",XT-2002|2020-005979-12,"April 28, 2021","April 1, 2022","April 1, 2022","June 16, 2021","November 29, 2021","Multiprofile Hospital for Active Treatment "" St. Ekaterina"" - Dimitrovgrad - EOOD, COVID Departement, Dimitrovgrad, Bulgaria|University Multiprofile Hospital for Active Treatment - Plovdiv - AD, COVID Departement, Plovdiv, Bulgaria|Complex Oncological Center - Ruse Ltd, COVID Departement, Ruse, Bulgaria|Specialized Hospital for Active Treatment for Pneumophtisiatrics Diseases Dr. Dimitar Gramatikov - Ruse - EOOD, Departement of Pneumology, Ruse, Bulgaria|5th Multiprofile hospital for Active Treatment - Sofia - EAD, Departement of Pneumology and Phtisiatric, Sofia, Bulgaria|Evangelismos General Hospital of Athens, Critical Care Departement, Athens, Greece|""Sotiria"" General Hospital of Chest Diseases of Athens, 3rd Department of Medicine of University of Athens, Athens, Greece|University Hospital of Heraklion, Department of Internal Medicine & Infectious Diseases Unit, Heraklion, Greece|AHEPA University General Hospital of Thessaloniki, Infectious Diseases Division of 1st Internal Medicine Department, Thessaloniki, Greece|""Hippokration"" General Hospital of Thessaloniki, 3rd Department of Pediatrics, Thessaloniki, Greece|Leon Daniello Clinical Hospital of Pneumoftiziology, Cluj-napoca, Romania|Hospital for Infectious Diseases and Pneumology ""Victor Babeş"" Craiova, Craiova, Romania|Military Field Hospital ROL-2, Otopeni, Romania|Pius Brinzeu County Emergency Clinical Hospital Timisoara, Timisoara, Romania|Ramón y Cajal University Hospital, Madrid, Spain|Puerta del Hierro University Hospital, Majadahonda, Spain|Bağcılar Medipol Mega Universite Hastanesi, Bağcılar, Turkey|Istanbul University Cerrahpasa-Cerrahpasa Medical Faculty, Fatih, Turkey", ,https://ClinicalTrials.gov/show/NCT04928430
NCT04757857,COVID-19 Antithrombotic Rivaroxaban Evaluation,CARE,Recruiting,No Results Available,COVID-19,Rivaroxaban 10 mg,Venous thromboembolic events (VTE)|Mechanical ventilation free-survival|Major Adverse Cardiovascular Events (MACE)|Out-of-hospital death not attributed to major injury|Time from randomization to hospitalization|Length of Hospitalization|Hospitalization in Intensive Care Unit|Clinical requirement of mechanical ventilation|Clinical duration of mechanical ventilation|Composite vascular endpoint I|Composite vascular endpoint II|Major Bleeding|Mortality,Hospital Alemão Oswaldo Cruz|Bayer|Hospital Israelita Albert Einstein|Hospital do Coracao|Hospital Sirio-Libanes|Hospital Moinhos de Vento|Brazilian Research In Intensive Care Network|Brazilian Clinical Research Institute,All,18 Years, ,Adult|Older Adult,Phase 4,1000,Other|Industry,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,36066320.5.1001.0070,"September 29, 2020","September 28, 2021","October 30, 2021","February 17, 2021","August 25, 2021","Clínica Senhor do Bonfim, Feira de Santana, Bahia, Brazil|Hospital Maternidade São Vicente de Paulo, Barbalha, Ceará, Brazil|Hospital de Base do Distrito Federal, Brasília, Distrito Federal, Brazil|Hospital de Campanha Covid-19 Goiânia/Sesgo, Goiânia, Goias, Brazil|Hospital Estadual de Urgências de Trindade/SESGO, Trindade, Goias, Brazil|Núcleo de Pesquisa Clínica do Hospital Vera Cruz, Belo Horizonte, Minas Gerais, Brazil|Hospital São Lucas, Belo Horizonte, Minas Gerais, Brazil|Santa Casa de Misericórdia de Passos, Passos, Minas Gerais, Brazil|Hospital Universitário Regional de Maringá, Maringá, Paraná, Brazil|Beneficencia Nipo Brasileira Da Amazonia, Belém, Para, Brazil|Hospital Adventista de Belém, Belém, Para, Brazil|Associação Dr. Bartholomeu Tacchini, Bento Gonçalves, Rio Grande Do Sul, Brazil|Hospital São Vicente de Paulo, Passo Fundo, Rio Grande Do Sul, Brazil|Hospital das Clínicas de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Universitario de Santa Maria, Santa Maria, Rio Grande Do Sul, Brazil|Clínica Procárdio Ltda, Blumenau, Santa Catarina, Brazil|H&W Cardiologia LTDA, Joinville, Santa Catarina, Brazil|Irmandade santa Casa de Araras, Araras, São Paulo, Brazil|Alphacor Cardiologia Clínica e Diagnóstica LTDA, Barueri, São Paulo, Brazil|Maestri e Kormann Consultoria Medico-Cientifica LTDA - EPP, Blumenau, São Paulo, Brazil|Hospital Regional do Litoral Norte - Instituto Sócrates Guanaes, Caraguatatuba, São Paulo, Brazil|Hospital Santos Dumont Litoral Norte, Caraguatatuba, São Paulo, Brazil|Hospital de Corderiopolis, Cordeiropolis, São Paulo, Brazil|Hospital Regional Jorge Rossman - Instituto Sócrates Guanaes, Itanhaém, São Paulo, Brazil|Hospital Carlos Fernando Malzoni, Matão, São Paulo, Brazil|Hospital Moinhos de Vento, Porto Alegre, São Paulo, Brazil|Hospital Regional de Registro - Instituto Sócrates Guanaes, Registro, São Paulo, Brazil|Hospital Unimed Ribeirão Preto, Ribeirão Preto, São Paulo, Brazil|Kaiser Clinica e Hospital Dia, São José do Rio Preto, São Paulo, Brazil|Braile Hospital Dia Ltda, São José Do Rio Preto, São Paulo, Brazil|Hospital Policlin, São José Dos Campos, São Paulo, Brazil|Hospital Regional de São José dos Campos - Instituto Sócrates Guanaes, São José Dos Campos, São Paulo, Brazil|Santa Casa de Misericórdia de Votuporanga, Votuporanga, São Paulo, Brazil|International Research Center - Hospital Alemão Oswaldo Cruz, São Paulo, Brazil|Hospital Leforte Liberdade, São Paulo, Brazil|Incor - Instituto do Coração do Hospital das Clínicas da FMUSP, São Paulo, Brazil", ,https://ClinicalTrials.gov/show/NCT04757857
NCT04482621,Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial,DART,Recruiting,No Results Available,COVID-19,Decitabine|Placebo Saline,Change in clinical state as assessed by a 6-point ordinal scale|Safety as assessed by adverse events|Change in oxygenation index|Change in fraction of inspired oxygen|Time (days) to clinical improvement|Overall survival|Length of stay in hospital|Ventilator free days|Time to Polymerase chain reaction (PCR) negativity|Percentage of patients with National Early Warning Score 2 of 3 or more,Johns Hopkins University,All,18 Years, ,Adult|Older Adult,Phase 2,40,Other,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",IRB00247544,"September 14, 2020",February 2022,March 2022,"July 22, 2020","September 28, 2021","Johns Hopkins University, Baltimore, Maryland, United States", ,https://ClinicalTrials.gov/show/NCT04482621
NCT04404179,Setting up a COVID-19 Care Facility at a Prison in Pakistan, ,Completed,No Results Available,COVID-19,COVID-19 FACILITY,Recovery|Mortality|ICU admission,"Services Institute of Medical Sciences, Pakistan",All, , ,Child|Adult|Older Adult, ,69,Other,Observational, ,Observational Model: Case-Only|Time Perspective: Prospective,CovJ,"March 27, 2020","May 2, 2020","May 2, 2020","May 27, 2020","May 29, 2020","Camp Jail / COVID-19 CARE FACILITY/ SIMS, Lahore, Pakistan", ,https://ClinicalTrials.gov/show/NCT04404179
NCT04474483,Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19,COVID-19,Recruiting,No Results Available,COVID-19,Melatonin|Placebo (Methylcellulose) capsule,Cumulative Incidence of Treatment-Emergent Adverse Events|Hospitalization|COVID-19 related symptoms|Rate of resolution of COVID-19 related symptoms|Mortality,State University of New York at Buffalo,All,18 Years, ,Adult|Older Adult,Phase 2,30,Other,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",UBMELCOVID19,"November 6, 2020","December 31, 2021","December 31, 2021","July 16, 2020","June 11, 2021","University at Buffalo, Buffalo, New York, United States", ,https://ClinicalTrials.gov/show/NCT04474483
NCT05096091,"International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)",InVITE,Recruiting,No Results Available,COVID-19, ,"1. To characterize immunogenicity (by measurement of anti-Spike [S] antibody [Ab]) of available COVID-19 vaccines in the overall study population, in each of the countries and in defined subgroups|Evaluate duration of immunogenicity|Evaluate immunogenicity in predefined subgroups (by age, body mass index [BMI], comorbidities, HIV, breakthrough infection, or evidence of prior infection with SARS-CoV-2).|Characterize virus causing breakthrough infections using viral genomic sequencing.|Compare immunogenicity between different vaccines.|Evaluate infection rates after vaccination.","National Institute of Allergy and Infectious Diseases (NIAID)|Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo|Partnership for Clinical Research in Guinea/Partenariat de Recherche Clinique en Guinée (PREGUI)|National Institute of Health Research and Development, Ministry of Health Republic of Indonesia|Partnership for Research on Ebola Virus in Liberia (PREVAIL)|University Clinical Research Center, Mali|National Institute of Medical Sciences and Nutrition, Salvador Zubiran|Onom Foundation and Liver Center",All,18 Years, ,Adult|Older Adult, ,10000,NIH|Other,Observational, ,Observational Model: Ecologic or Community|Time Perspective: Cross-Sectional,InVITE 01,"August 16, 2021",August 2024,February 2025,"October 27, 2021","January 12, 2022","National Institute for Biomedical Research/Institut National de Recherche Biomédicale (INRB), Gombe, Kinshasa, Congo, The Democratic Republic of the|Partnership for Clinical Research in Guinea/Partenariat de Recherche Clinique en Guinée (PREGUI), Conakry, Guinea|National Institute of Health Research and Development (NIHRD), Ministry of Health, Republic of Jakarta - RSU Kabupaten Tangerang, Tangerang, Indonesia|Partnership for Research in Vaccines and Infectious Diseases in Liberia (PREVAIL) - Duport Road Health Center, Monrovia, Liberia|University Clinical Research Center (UCRC) University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali|LaRed Network, Mexico City, Mexico|LaRed Network, Monterrey, Mexico|LaRed Network, Oaxaca, Mexico|LaRed Network, Tapachula, Mexico|Onom Foundation and Liver Center, Ulaanbaatar, Mongolia", ,https://ClinicalTrials.gov/show/NCT05096091
NCT04716426,APT™ T3X on the COVID-19 Contamination Rate, ,Completed,Has Results,COVID-19,Tetracycline hydrochloride 3%|Placebo,COVID-19 Contamination Rate.|Number of Participants With Adverse Events|Average Number of Adverse Events|Days Over Which an Adverse Event Was Reported|Other Virus or Bacteria Contamination Rate.,University of Nove de Julho|Santa Casa de Misericórdia de Porto Alegre,All,18 Years, ,Adult|Older Adult,Not Applicable,100,Other,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention",4.485.847,"January 28, 2021","March 25, 2021","March 25, 2021","January 20, 2021","April 8, 2021","April 8, 2021","Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil","
        |Study Protocol and Statistical Analysis Plan|https://ClinicalTrials.gov/ProvidedDocs/26/NCT04716426/Prot_SAP_000.pdf",https://ClinicalTrials.gov/show/NCT04716426
NCT05069636,Lymphatic Osteopathic Manipulative Medicine to Enhance Coronavirus (COVID-19) Vaccination Efficacy, ,Not yet recruiting,No Results Available,COVID-19,Lymphatic OMM|Light Touch,severe acute respiratory syndrome-associated coronavirus 2 (SARS-Cov-2) antibody levels,Rowan University,All,18 Years, ,Adult|Older Adult,Not Applicable,100,Other,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Other,PRO-2021-519,"November 15, 2021","February 28, 2023","February 28, 2023","October 6, 2021","November 10, 2021", , ,https://ClinicalTrials.gov/show/NCT05069636
NCT04853069,Oestrogen Treatment for COVID-19 Symptoms, ,Not yet recruiting,No Results Available,COVID-19,Transdermal estradiol gel,Evidence of disease progression for mild cases|Evidence of disease progression in hospitalised patients (moderate and severe cases)|Hospital mortality|Duration of hospital admission|Admission to ICU/ HDU facility|Need for renal replacement therapy|Ventilation|Time to being fit for hospital discharge,Hamad Medical Corporation|Laboratoires Besins International,All,18 Years, ,Adult|Older Adult,Phase 2,2000,Industry,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,MRC-05-099,"May 17, 2021","February 28, 2022","March 31, 2022","April 21, 2021","April 21, 2021","Hamad Medical Corporation, Doha, Qatar", ,https://ClinicalTrials.gov/show/NCT04853069
NCT05041907,Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV),PLATCOV,Recruiting,No Results Available,COVID-19,Favipiravir|Monoclonal antibodies|Ivermectin|No treatment|Remdesivir,"Rate of viral clearance for repurposed drugs|Rate of viral clearance of positive control (monoclonal antibodies) over time relative to the negative control|Rate of viral clearance for small novel molecule drugs|Viral kinetic levels in early COVID-19 disease|Number of antiviral treatment arms that show a positive signal (>90% probability of >5% acceleration in viral clearance)|Rates of viral clearance by treatment arm, as compared against REGN-COV2 (monoclonal antibody cocktail)",University of Oxford,All,18 Years,50 Years,Adult,Phase 2,750,Other,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,VIR21001,"September 30, 2021",August 2023,August 2023,"September 13, 2021","January 28, 2022","Universidade Federal de Minas Gerais, Minas Gerais, Brazil|Vajira hospital, Bangkok, Thailand|Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand|Bangplee Hospital, Samut Prakan, Thailand", ,https://ClinicalTrials.gov/show/NCT05041907
NCT04479358,Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19,COVIDOSE-2,Recruiting,No Results Available,COVID-19,Tocilizumab|Tocilizumab|Standard of Care|Standard of Care,Time to Recovery|Achievement of Recovery|Overall Survival|Hospital Length of Stay|Clinical Response: Maximum Temperature (Tmax) Response|Clinical Response: Rate of Non-Elective Invasive Mechanical Ventilation|Clinical Response: Duration of Non-Elective Invasive Mechanical Ventilation|Clinical Response: Time to Non-Elective Invasive Mechanical Ventilation|Clinical Response: Rate of Vasopressor/Inotrope Utilization|Clinical Response: Duration of Vasopressor/Inotrope Utilization|Clinical Response: Time to Vasopressor/Inotrope Utilization|Clinical Response: Duration of Increased Supplemental Oxygen from Baseline|Biochemical Response: C-reactive Protein Response Rate|Safety: Rate of Secondary Infection,University of Chicago,All,18 Years, ,Adult|Older Adult,Phase 2,332,Other,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,IRB20-1179,"September 10, 2020","March 1, 2022","March 1, 2023","July 21, 2020","December 2, 2021","University of Chicago Medicine, Chicago, Illinois, United States", ,https://ClinicalTrials.gov/show/NCT04479358
NCT04389658,Contagiousness and Immunogenicity Status of COVID-19 in Asymptomatic Population (COVID-19 CONDITION),CONDITION,Completed,No Results Available,COVID-19, ,Prevalence of contagiousness in asymptomatic individuals by PCR|Ratio of asymptomatic immunized (IgA/IgM and IgG) population|Description of demographic characteristics,Igenomix,All, , ,Child|Adult|Older Adult, ,1526,Industry,Observational, ,Observational Model: Other|Time Perspective: Retrospective,IGX1-COV-XS-20-01,"May 7, 2020","June 10, 2020","August 25, 2020","May 15, 2020","October 9, 2020","Igenomix, Paterna, Valencia, Spain", ,https://ClinicalTrials.gov/show/NCT04389658
NCT04342689,The Role of Resistant Starch in COVID-19 Infection, ,Recruiting,No Results Available,COVID-19,Dietary Supplement containing resistant starch|Placebo Starch,Rates of hospitalization for a COVID-19 related complication (Phase 3)|Time to clinical recovery (TTCR) (Phase 2)|Symptom Severity Score (Phase 2),Yale University|University of Michigan,All,19 Years, ,Adult|Older Adult,Phase 2|Phase 3,1500,Other,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",2000027887,"June 3, 2020","March 1, 2022","March 1, 2022","April 13, 2020","September 17, 2021","Yale University, New Haven, Connecticut, United States|University of Michigan, Ann Arbor, Michigan, United States", ,https://ClinicalTrials.gov/show/NCT04342689
NCT05027464,Developing and Testing a COVID-19 Vaccination Acceptance Intervention,CoVAcS,Not yet recruiting,No Results Available,COVID-19 Vaccination,Moving to COVID-19 Vaccine Acceptance Intervention,COVID-19 Vaccination Status|Seasonal Influenza Vaccination Status|Survey of Veterans from Intervention and Usual Care who did and did not receive COVID-19 vaccination|Qualitative Interview with purposive subset of Veterans from Intervention and Usual Care who did and did not receive COVID-19 vaccination|Qualitative Interviews with VA staff and Healthcare Providers|Secondary Analysis of VA National Data,VA Office of Research and Development|VA Bedford Healthcare System,All,18 Years, ,Adult|Older Adult,Not Applicable,2500,U.S. Fed|Other,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Health Services Research",SDR 21-141,"February 15, 2022","July 3, 2023","September 30, 2023","August 30, 2021","January 25, 2022","Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR, North Little Rock, Arkansas, United States|San Francisco VA Medical Center, San Francisco, CA, San Francisco, California, United States", ,https://ClinicalTrials.gov/show/NCT05027464
NCT04666116,Changes in Viral Load in COVID-19 After Probiotics, ,Recruiting,No Results Available,COVID-19,Dietary supplementation in patients with covid disease admitted to hospital,Viral load during the period of admission to the nasopharyngeal smear.|Clinical indicators on admission and every 48 hours thereafter|Analytical parameters|Mobility|Microbiome analysis in feces,Hospital de Sagunto|Biopolis S.L.|Laboratorios Heel España,All,18 Years,99 Years,Adult|Older Adult,Not Applicable,96,Other|Industry,Interventional, ,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,HdeSagunto,"April 1, 2020",December 2020,February 2021,"December 14, 2020","December 16, 2020","Hospital de Sagunto, Sagunto, Valencia, Spain|Hospital de Sagunto, Valencia, Spain", ,https://ClinicalTrials.gov/show/NCT04666116
NCT04369820,C5a Receptor Expression - COVID-19 (C5-COV),C5-COV,Recruiting,No Results Available,COVID-19,draw blood,Show an overexpression of C5a receptor in patients with ARDS secondary to COVID-19 compared to control patients (patients with COVID-19 without respiratory distress and healthy volunteers).,Assistance Publique Hopitaux De Marseille|Innate Pharma,All,18 Years, ,Adult|Older Adult,Not Applicable,100,Other|Industry,Interventional, ,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,2020-14|IDRCB,"March 31, 2020",September 2020,November 2020,"April 30, 2020","May 4, 2020","Assistance Publique Hôpitaux de Marseille, Marseille, France", ,https://ClinicalTrials.gov/show/NCT04369820
NCT04401423,TXA127 for the Treatment of Severe COVID-19, ,Completed,No Results Available,COVID-19,TXA127|Placebo,Change of serum creatinine|Number of participants requiring intubation and ventilatory support|Change in number of deceased participants|Number of participants requiring dialysis|Number of participants requiring a vasopressors|Change in blood inflammatory markers|Percent change in supplemental oxygen requirements,Columbia University|Constant Therapeutics LLC,All,18 Years, ,Adult|Older Adult,Phase 2,22,Other|Industry,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",AAAT0535,"February 10, 2021","June 10, 2021","June 10, 2021","May 26, 2020","July 29, 2021","Columbia University Irving Medical Center, New York, New York, United States", ,https://ClinicalTrials.gov/show/NCT04401423
NCT04470557,Relation Between Lab Finding and COVID-19 Severity, ,Not yet recruiting,No Results Available,COVID-19,"D-dimer,CBC.ESR,CRP,|Liver function tests ,serum ferritin and PCR for COVID-19 .",Estimation of severity of patients with COVID-19 in relation to Laboratory findings.,Assiut University,All, , ,Child|Adult|Older Adult, ,100,Other,Observational, ,Observational Model: Other|Time Perspective: Cross-Sectional,RLCS,"July 15, 2020","October 1, 2020","December 1, 2020","July 14, 2020","July 14, 2020", , ,https://ClinicalTrials.gov/show/NCT04470557
NCT04558372,Genosvid Diagnostic Test for Early Detection of COVID-19, ,Completed,No Results Available,COVID-19,exhaled breath sampling|exhaled breath sampling|exhaled breath sampling,Diagnostic accuracy of electronic nose signal in COVID-19,Gadjah Mada University,All,4 Years, ,Child|Adult|Older Adult,Not Applicable,1999,Other,Interventional, ,"Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic",1.6/2020,"April 1, 2020","December 12, 2020","December 12, 2020","September 22, 2020","December 29, 2020","RS Bhayangkara Tk I R.Said Soekanto, Jakarta, Indonesia|Saiful Anwar, Malang, Indonesia|Dr Sardjito Hospital, Yogyakarta, Indonesia|Bambanglipuro Hospital, Yogyakarta, Indonesia|Bhayangkara Tk III Polda DIY, Yogyakarta, Indonesia|RS Akademik UGM, Yogyakarta, Indonesia|RSPAU Hardjolukito, Yogyakarta, Indonesia|RST Tk III Dr Soetarto, Yogyakarta, Indonesia", ,https://ClinicalTrials.gov/show/NCT04558372
NCT05155527,A Double-blind Randomized Controlled Trial of Ivermectin With Favipiravir in Mild-to-moderate COVID-19 Patients,IFCOV,Not yet recruiting,No Results Available,COVID-19,Ivermectin Tablets|Placebo,The rate of SARS-CoV-2 viral clearance|Mortality rate|Progression to severe disease|Duration of admission|Oxygen requirement|Proportions of SARS-CoV-2 viral clearance,Mahidol University|Prince of Songkla University,All,18 Years,65 Years,Adult|Older Adult,Phase 2,200,Other,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CREC067/64BR-MED46,December 2021,June 2022,June 2022,"December 13, 2021","December 13, 2021", , ,https://ClinicalTrials.gov/show/NCT05155527
NCT04587323,VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease, ,Recruiting,No Results Available,COVID-19 Disease, ,Laboratory Assays|VEGF-A|VEGF-C|VEGF-D|Tie-2|Flt-1|PlGF|FGF,University of Alabama at Birmingham,All,18 Years, ,Adult|Older Adult, ,100,Other,Observational, ,Observational Model: Cohort|Time Perspective: Prospective,IRB-300005378,"May 22, 2020","March 20, 2023","May 20, 2023","October 14, 2020","November 23, 2021","University of Alabama at Birmingham, Birmingham, Alabama, United States", ,https://ClinicalTrials.gov/show/NCT04587323
NCT05157269,Trial to Evaluate Nitazoxanide for Treatment of Mild COVID-19 in Subjects Not at High Risk of Severe Illness, ,Not yet recruiting,No Results Available,COVID-19,Nitazoxanide|Placebo|Vitamin Super-B Complex,Time to sustained COVID-19 Recovery,Romark Laboratories L.C.,All,12 Years, ,Child|Adult|Older Adult,Phase 3,600,Industry,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RM08-3011,January 2022,March 2022,April 2022,"December 14, 2021","December 14, 2021", , ,https://ClinicalTrials.gov/show/NCT05157269
NCT04392141,Colchicine Plus Phenolic Monoterpenes to Treat COVID-19, ,Completed,Has Results,COVID-19,Standard Treatment|Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions,Mortality Rate|SpO2|Length of Hospitalization|Lymphocyte Count|Serum Lactate Dehydrogenase,Kermanshah University of Medical Sciences,All,10 Years, ,Child|Adult|Older Adult,Phase 1|Phase 2,120,Other,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",1399.062,"April 1, 2020","November 1, 2020","November 1, 2020","May 18, 2020","April 20, 2021","April 20, 2021","Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran, Kermanshah, Iran, Islamic Republic of","
        |Study Protocol|https://ClinicalTrials.gov/ProvidedDocs/41/NCT04392141/Prot_000.pdf|
        |Statistical Analysis Plan|https://ClinicalTrials.gov/ProvidedDocs/41/NCT04392141/SAP_001.pdf",https://ClinicalTrials.gov/show/NCT04392141
NCT04418284,Online Learning of Veterinary Anatomy During COVID-19 Pandemic, ,Completed,No Results Available,COVID-19,survey,Measure the students' interest in studying anatomy on-line.|Assess the easiness of using technology during studying anatomy online|Assess the student satisfaction regarding the provided study materials,South Valley University,All,17 Years,35 Years,Child|Adult, ,1517,Other,Observational, ,Observational Model: Other|Time Perspective: Cross-Sectional,2-2020,"June 5, 2020","November 5, 2020","November 5, 2020","June 5, 2020","March 16, 2021","South Valley University, Qinā, Egypt", ,https://ClinicalTrials.gov/show/NCT04418284
NCT04449718,Vitamin D Supplementation in Patients With COVID-19, ,Completed,No Results Available,COVID-19,Vitamin D|Placebo,Length of hospitalization|Mortality|Number of cases admitted to Intensive Care Unit (ICU)|Length of use of mechanic ventilator|Number and severity of symptoms|Inflammatory markers|C-reactive protein|Vitamin D|Creatinine|Calcium|Physical activity,University of Sao Paulo,All,18 Years, ,Adult|Older Adult,Not Applicable,240,Other,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",30959620.4.0000.0068,"June 1, 2020","October 7, 2020","October 7, 2020","June 29, 2020","November 17, 2020","Clinical Hospital of the School of Medicine, University of Sao Paulo, Sao Paulo, Brazil", ,https://ClinicalTrials.gov/show/NCT04449718
NCT05107440,BREATHE: Virtual Self-management for Long COVID-19, ,Not yet recruiting,No Results Available,COVID-19,BREATHE,Self-efficacy to manage symptoms|Self-efficacy to manage daily activities|Self-efficacy to manage emotions|Fatigue severity (FACIT-F)|Medical Research Council (MRC) breathlessness scale grade|Post-COVID-19 Functional Scale (PCFS) grade|Recovery grade|Physical functioning subscale score|Role limitations due to physical health subscale score|Role limitations due to emotional problems subscale score|Emotional well-being subscale score|Social functioning subscale score|Energy/fatigue subscale score|Pain subscale score|General health subscale score|Physical component score|Mental component score,University of Calgary,All,18 Years, ,Adult|Older Adult,Not Applicable,36,Other,Interventional, ,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,REB21-1359,"October 25, 2021","April 30, 2022","October 31, 2022","November 4, 2021","November 4, 2021", , ,https://ClinicalTrials.gov/show/NCT05107440
NCT04978233,The Opal - COVID-19 Study, ,Completed,No Results Available,COVID-19,"sociodemographic and health, daily self-assessment, and feasibility of using the Opal app for COVID",Change in the acceptability of the Opal app for COVID-19|Change in the usability of the Opal app for COVID-19|Contact with the healthcare team|Change in symptoms|Patient satisfaction with scheduled teleconsultations|Change in vital signs temperature|Change in vital signs respiration rate|Change in vital signs oxygen saturation|Change in vital signs heart rate|Change in vital signs blood pressure,Dr. Bertrand Lebouche|McGill University Health Centre/Research Institute of the McGill University Health Centre,All,18 Years, ,Adult|Older Adult, ,50,Other,Observational, ,Observational Model: Other|Time Perspective: Prospective,2021-6763,"December 8, 2020","March 31, 2021","March 31, 2021","July 27, 2021","July 27, 2021","Research Institute of the McGill University Health Centre, Montréal, Quebec, Canada", ,https://ClinicalTrials.gov/show/NCT04978233
NCT05157243,Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness, ,Not yet recruiting,No Results Available,COVID-19,Nitazoxanide|Vitamin Super-B Complex|Placebo|Standard of Care,Proportion of participants progressing to severe COVID-19 or death from any cause,Romark Laboratories L.C.,All,12 Years, ,Child|Adult|Older Adult,Phase 3,2000,Industry,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",RM08-3010,January 2022,April 2022,May 2022,"December 14, 2021","December 14, 2021", , ,https://ClinicalTrials.gov/show/NCT05157243
NCT05092581,"COVID-19 Study of Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19", ,Not yet recruiting,No Results Available,COVID-19,casirivimab+imdevimab,Concentrations of casirivimab+imdevimab in serum over time|Proportion of patients with treatment-emergent serious adverse events (SAEs)|Proportion of patients with infusion-related reactions|Proportion of patients with hypersensitivity reactions|Incidence of anti-drug antibodies (ADA) to casirivimab+imdevimab over time|Incidence of neutralizing antibodies (NAb) to casirivimab+imdevimab over time,Regeneron Pharmaceuticals,All,17 Years, ,Child,Phase 1,40,Industry,Interventional, ,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,R10933-10987-COV-2114|2021-004535-84,"December 20, 2021","June 9, 2023","June 9, 2023","October 25, 2021","October 25, 2021", , ,https://ClinicalTrials.gov/show/NCT05092581
NCT04324489,DAS181 for Severe COVID-19: Compassionate Use, ,Completed,No Results Available,COVID-19,DAS181,Improved clinical status|Return to room air|SARS-CoV-2 RNA|Discharge|Death,"Renmin Hospital of Wuhan University|Ansun Biopharma, Inc.",All,18 Years,70 Years,Adult|Older Adult,Not Applicable,4,Other|Industry,Interventional, ,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,DAS181-SARS-CoV-2,"March 6, 2020","April 16, 2020","April 30, 2020","March 27, 2020","May 5, 2020","Renmin Hospital of Wuhan University, Wuhan, Hubei, China", ,https://ClinicalTrials.gov/show/NCT04324489
NCT04370262,Multi-site Adaptive Trials for COVID-19, ,Completed,No Results Available,COVID-19,SOC + Intravenous Famotidine|SOC + Placebo,Mortality|Virologic response to study treatment detected in blood|Virologic clearance in nasal swab and/or lower respiratory secretions|Clinical Severity,Northwell Health,All,18 Years, ,Adult|Older Adult,Phase 3,233,Other,Interventional, ,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",20-0268,"April 7, 2020","September 7, 2020","September 7, 2020","April 30, 2020","December 11, 2020","Southside Hospital, Bay Shore, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Northern Westchester Hospital, Mount Kisco, New York, United States|Lenox Hill Hospital, New York, New York, United States|Long Island Jewish Medical Center, Queens, New York, United States", ,https://ClinicalTrials.gov/show/NCT04370262
